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ABSTRACT
The successful use of chemotherapy in the treatment of breast cancer is confounded by
the development of clinical drug resistance in a large number of cases. One mechanism
of resistance, multidrug resistance (MDR), is associated with expression of a 170kDa
transmembrane protein called P-glycoprotein (P-gp) which acts as an energy-dependent
drug efflux pump. Although P-gp can be encoded by several MDR genes it is only
expression of the mdr-1 gene which is associated with MDR in humans. P-gp has been
identified in several human tissues and tumours but previous studies have failed to
provide clear evidence of its presence in human breast cancer.
Detection of P-gp, by immunohistochemistry using specific monoclonal antibodies,
allowed confirmation of P-gp expression at low levels in the majority of 29 untreated,
primary breast cancers suggesting a population of resistant cells was present even before
exposure to cytoxic drugs. Furthermore this expression was detected in stromal cells,
as well as malignant cells, and this stromal cell immunostaining has been confirmed as
mdr-1 expression by competitive inhibition using a specific blocking peptide.
Examination of paired samples of normal breast and tumour from the same patient
revealed P-gp expression only in ductal epithelial cells, but not stromal cells, of normal
breast. Finally those patients whose tumours had the highest P-gp expression in
malignant cells appeared to have a worse prognosis in terms of disease-free survival.
Following confirmation that the drug-efflux pump could be reversed in vitro by several
modulating agents one of these compounds, quinidine, was selected for further study.
It was established that tumour quinidine concentrations, adequate for MDR modulation
in vitro, could be achieved both in an animal model of MDR and in human breast
cancers. This led to attempts to use quinidine as a potential in vivo MDR modulator
in a human MDR xenograft in the mouse. As well as producing a significant growth
delay quinidine also appeared to redistribute intracellular epirubicin in this model with
increased nuclear autofluorescence compared to controls.
This demonstration of the activity of a resistance modulator in vivo, together with
confirmation of MDR expression in breast cancer, provides a sound basis for attempts
to modulate MDR in patients. The combination of epirubicin and quinidine can be
given to patients with breast cancer without any increase in systemic toxicity. Quinidine,
however, did not increase total tumour epirubicin levels and had no apparent effect on
intracellular distribution. A Phase II placebo-controlled double blind trial in the West
of Scotland to examine the effects of quinidine on response to chemotherapy with
epirubicin in patients with locally advanced or metastatic breast cancer is underway and




Breast cancer is the commonest cancer in women in the West of Scotland, with
an incidence of 91.4 per 100,000 women, which was responsible for 693 deaths
per annum during 1984-1988. It is now known that even thirty years after
presentation with breast cancer the risk of death from recurrent disease is
significantly increased when compared with a normal population of the same age
distribution (Brinkley & Haybittle, 1984). There is therefore good evidence to
support the theory that breast cancer is a systemic disease, with micrometastases
already present at the time of initial referral. Thus it is essential to improve
methods of systemic treatment in order to influence the clinical outcome of these
patients. Chemotherapy is now widely used both as an adjuvant treatment in
high risk groups to prevent disease recurrence and in the treatment of advanced
breast cancer. When used as an adjuvant therapy the combination of
cyclophosphamide, methotrexate and 5-fluorouracil (CMF) does significantly
reduce the risk of relapse, at least in women < 50 years (Early Breast Cancer
Trialists' Collaborative Group, 1988)
DRUG RESISTANCE
The use of cytotoxic agents in the treatment of breast cancer is confounded by
the development of clinical drug resistance in a large number of cases. Unlike
intrinsic drug resistance, where tumours infrequently respond to initial cytotoxic
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therapy eg. colonic carcinoma, most breast cancers do initially respond to
chemotherapy only to relapse at a later stage as a result of acquired drug
resistance. The most active single agents in the treatment of advanced breast
cancer are anthracyclines with a response rate of 40-50% in previously untreated
patients (Young et al, 1981). Although most anthracyclines are cardiotoxic after
a certain cumulative dose their use is limited not by this but by the development
of clinical drug resistance. As the various cellular mechanisms which underly this
development of a population of resistant cells are identified it is hoped that
strategies can be planned to circumvent them. The best characterised
mechanism, known to be induced by anthracyclines, is called multidrug resistance
(MDR). In view of the common use of anthracyclines in the treatment of breast
cancer this mechanism may well be relevant to this tumour type.
THE MULTIDRUG RESISTANCE PHENOTYPE
The most striking feature of the MDR phenotype is that cells selected for
resistance to a specific cytotoxic drug, by stepwise incubation in increasing
amounts of the drug, can be cross-resistant to other structurally unrelated
cytotoxic agents. This was first described in Chinese hamster lung cells selected
for resistance in vitro to Actinomycin D but which displayed cross-resistance to
vinblastine, vincristine and daunomycin (Biedler & Riehm, 1970). The drugs
associated with the MDR phenotype are anthracyclines, vinca alkaloids and
etoposide (Seeber et al, 1982). Although these drugs are not structurally similar,
and have different intracellular targets, they are all hydrophobic compounds
derived from natural products and they appear to share a common mechanism
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of cellular drug resistance. Further studies with both animal (Skovsgaard et al,
1978; Inaba et al, 1978) and human (Fojo et al, 1985) continuous cell lines have
shown that this cross-resistance is related to decreased intracellular drug
accumulation which is correlated to the presence of a specific 170,000 dalton
transmembrane protein (Riordan et al, 1985). This protein, first described in
Chinese hamster ovary cells selected for resistance to colchicine, was termed P-
glycoprotein (P-gp) as the cells were thought to display altered membrane
Permeability (Juliano & Ling, 1976). This glycoprotein is present in many MDR
cell types, but not in the corresponding drug-sensitive wild-types, and is thought
to act as an energy-dependent drug-efflux pump (Chen et al, 1986).
P-GLYCOPROTEIN
The entire structure and amino acid sequences of both murine and human P-
gp have been derived from the specific genes which encode them (Gros et al,
1986; Chen et al, 1986). Recent studies have shown that P-gp is encoded by a
family of three genes in rodents and two genes in humans (Ng et al, 1989).
Although this glycoprotein is highly conserved throughout several mammalian
species, and comparison of the various P-gp isoforms indicates a similar overall
structure, only certain P-gp isoforms actually confer the MDR phenotype. The
link between the human mdr-1 gene and the development of the MDR phenotype
has been confirmed by transfer of genomic DNA from human KB carcinoma
cells into drug-sensitive mouse NIH 3T3 cells, thereby inducing the same pattern
of resistance in the recipient cells as their donor cells (Shen et al, 1986). Both
mdr-1 and mdr-2 are located on chromosome 7q (Gottesman & Pastan, 1988) but
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only expression of mdr-1 is associated with MDR. Identification of the amino
acid sequences of human P-gp has revealed several characteristics which support
its role as a transport protein. The 1280 amino acid molecule encoded by mdr-
1 consists of a tandem duplication, suggesting that the two halves were generated
by a gene duplication event. Each half consists of six putative transmembrane
regions each containing 21 amino acids and is homologous to the HlyB protein,
an Escherichia coli membrane protein required for the export of alpha-
haemolysin (Gerlach et al, 1986). In addition each half contains nucleotide
binding sequences homologous to regions found in transport proteins found in
Escherichia coli (Gilson et al, 1982) and Salmonella typhimurium (Higgins et al,
1986).
From the above evidence it is possible to suggest a model for P-gp whereby
energy derived from ATP hydrolysis is coupled to drug transport out of the cell
via the transmembranous part of the molecule. This would suggest that P-gp can
bind reversibly to drugs to allow release at the cell surface and more than one
binding site may be present to bind structurally unrelated drugs. Specific
vinblastine-binding sites have been confirmed, by photoaffinity labelling with
vinblastine analogues in a MDR human KB carcinoma cell line, KB-C4, which
were not present in the parental cell line, KB-31 (Cornwell et al, 1986).
Furthermore this binding could be inhibited by vincristine and daunomycin but
not by colchicine and Actinomycin D providing supportive evidence for more than
one binding site. The vinblastine-binding protein has been confirmed as P-gp by
immunoprecipitation with the monoclonal antibody to P-gp, C219 (Cornwell et
al, 1987).
5
The model of P-gp as an energy-dependent drug efflux pump fits well with the
increased chemoresistance and decreased intracellular drug accumulation found
in MDR cell lines. However not all P-gp isoforms are associated with the MDR
phenotype and the different MDR genes may code for slight alterations in the
structure of P-gp which may modulate its function. Post-translational
modifications eg. phosphorylation have been found in vitro and it is interesting
to note that two agents which can reverse the drug efflux pump, verapamil and
trifluoroperazine, can also increase phosphorylation (Hamada et al, 1987).
"ATYPICAL" MULTIDRUG RESISTANCE
Although the most consistent biochemical change in MDR cells is the expression
of P-gp recent studies have found cell lines which display the MDR phenotype
but which do not express P-gp. This form of MDR, termed "atypical" MDR
(Beck et al, 1987), has been documented in several cell lines eg. the large cell
lung carcinoma line COR-L23 (Reeve et al, 1990) and the human leukaemia
HL60 cells (McGrath et al, 1987) and clearly suggests the existence of alternative
biochemical pathways that lead to the development of the MDR phenotype. Two
enzymes which have been implicated in "atypical" MDR to date are DNA
topoisomerase (I & II) and glutathione-S-transferase.
Topoisomerases are nuclear enzymes which control conformational changes in
DNA, by cleaving DNA strands, and are thus essential for vital cellular processes
during translation, transcription and mitosis (Zijlstra et al, 1990). These enzymes
are specific targets for certain anti-tumour drugs which act by stabilising a
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"cleavable complex", an intermediate in the normal enzyme pathway, and this
stable complex appears to be cytotoxic (Zhang et al, 1990). The drugs involved
are anthracyclines, epipodophyllotoxins and amsacrine (Topoisomerase II) and
camptothecin (Topoisomerase I)(Smith et al, 1990). It is thought that cells
develop resistance to these drugs by down-regulation of the amount of
Topoisomerase or production of mutated forms of these enzymes (Tan et al,
1989). Since anthracyclines eg. epirubicin are used extensively in the treatment
of breast cancer this mechanism of resistance may well be relevant in the
development of clinical drug resistance.
Glutathione-S-transferase (GST), an enzyme involved in intracellular
detoxification, can neutralise potential toxins eg. cytotoxic drugs by conjugation
with glutathione. Elevated levels of this enzyme have been found in drug
resistant cells including the doxorubicin-resistant breast carcinoma cell line
MCF7adr (Batist et al, 1986). Furthermore elevation of cellular glutathione itself
may be linked to doxorubicin resistance since reduction of glutathione by
buthionine sulfoximine (BSO) has been shown to restore sensitivity to
doxorubicin-resistant cells in vitro (Flamilton et al, 1985).
It remains to be seen whether alterations to either Topoisomerase I or II and
glutathione-S-transferase contribute to the development of clinical drug resistance
in human tumours but the evidence implicating their role in "atypical" MDR in
vitro does seem convincing.
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MDR-1 / P-GLYCOPROTEIN EXPRESSION IN HUMAN TISSUES AND
TUMOURS
In humans the MDR phenotype is associated with expression of only one of the
two MDR genes, designated mdr-1. Human mdr-1 expression has been studied
in a variety of normal tissues by measurement of mdr-1 messenger RNA (mRNA)
and high levels were found in the kidney, adrenal, liver and gastrointestinal tract
(Fojo et al, 1987). The use of immunocytochemistry, with a monoclonal antibody
to P-gp (MRK16), has allowed more specific localisation of P-gp in the cells of
these organs (Thiebaut et al, 1987). In liver P-gp was found on the biliary
canalicular surface of hepatocytes and on the apical surface of epithelial cells in
pancreatic ducts, proximal kidney tubules and the gastrointestinal tract. These
findings led to the suggestion that P-gp may be involved in the normal transport
of metabolites or toxins in these cells and that P-gp expression in human tumours
may in fact be an enhanced form of a normal cellular transport or protective
mechanism. This is supported by recent evidence of mdr-1 mRNA, detected by
in situ hybridisation, in the zona glomerulosa and zona reticularis of human
adrenal cortical tumours (Harvie, personal communication). These two zones are
thought to be the main sites of production and secretion of aldosterone and
glucocorticoids.
MDR expression in tumours may be assessed either by measurement of mdr-1
mRNA or its protein product, P-gp. High levels of human mdr-1 mRNA have
been found in a variety of tumours including those arising from organs known to
express P-gp ie. adrenal, colon and kidney (Fojo et al, 1987). In addition this
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technique has shown significant expression in a series of untreated primary breast
cancers (Keith et al, 1990).
As mentioned previously P-gp itself may be detected by specific antibodies which
can be visualised by immuncytochemical techniques. C219, which reacts with an
internal epitope of P-gp, has revealed expression in acute non-lymphoblastic
leukaemia (Ma et al, 1987) as well as lung and ovarian carcinomas (Volm et al,
1989). In addition MRK16, which reacts with an external epitope, has detected
P-gp expression in lung cancer (Sugawara et al, 1988).
Previous studies of MDR expression in breast cancer specimens, either by
measurement of mdr-1 mRNA or expression of the protein product P-
glycoprotein, have failed to provide clear evidence that this particular mechanism
of resistance is relevant in the development of clinical drug resistance in human
breast cancer. In two studies which measured mdr-1 mRNA one found no
expression in 248 breast cancers, representing untreated primary and refractory
relapse specimens (Merkel et al, 1989), while low levels were found in 15% of
tumours in the other series (Goldstein et al, 1989). In contrast another study has
shown detectable levels of mdr-1 mRNA in the majority of 49 primary breast
cancers (Keith et al, 1990) with a wide variation in expression between different
tumours. These different results may be explained by heterogeneity of expression
of P-gp or alternatively by variable sensitivity of techniques depending on which
probe is used to detect mdr-1 mRNA. It was therefore essential to carry out a
detailed study of P-gp expression in human breast cancer in the first instance, by
using specific monoclonal antibodies to it, to try to resolve the conflicting
conclusions reached in previously published studies.
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MULTIDRUG RESISTANCE MODULATION
As mentioned at the beginning of this introduction it is hoped that the
identification of the various biochemical alterations in MDR cells may lead to
specific strategies to circumvent them. Specific agents are now known which are
capable of restoring sensitivity to a range of cytotoxic drugs in MDR-positive
cells. These agents, called resistance modifiers or modulators, are not themselves
cytotoxic and often share a common molecular structure (Rothenberg & Ling,
1989).
During the last decade there has been much interest in such non-
chemotherapeutic agents which may enhance the cytotoxicity of conventional
chemotherapy drugs such as doxorubicin. A number of calcium channel blocking
drugs eg. verapamil (Plumb et al, 1990), calmodulin inhibitors (Ganapathi et al,
1983) and quinidine (Tsuruo et al, 1984) have been shown to be effective in
enhancing the cytotoxicity of natural product anti-cancer drugs ie. vinca alkaloids
and anthracyclines.
VERAPAMIL
One of the earliest resistance modulators to be recognised was verapamil which
was found to enhance the chemosensitivity of MDR-positive cells to vincristine
or doxorubicin by increasing the intracellular accumulation of these drugs (Tsuruo
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et al, 1981). Although subsequent studies by the same group noted a minor
increase in intracellular drug in the drug-sensitive P388 leukaemia cells the
accumulation was much more marked in the drug-resistant counterpart (Tsuruo
et al, 1982). The use of verapamil as a resistance modifier has subsequently been
confirmed by other groups (Beck et al, 1986; Plumb et al, 1990).
Although the resistance modifying effect of verapamil has been established the
exact mechanism or mechanisms by which it exerts this effect remains unclear.
The recognition that MDR-positive cells do not have inhibitable calcium-
dependent calcium channels (Ramu et al, 1984) has led to the suggestion that its
calcium-blocking effect is separate from the modulating effect. Future studies
therefore looked for other mechanisms which could account for the modifying
effect of verapamil.
It is thought that verapamil, and other calcium-channel blockers, may bring about
this effect by inhibition of voltage-dependent potassium channels (De Coursey et
al, 1985) and certain calmodulin-dependent activities (Epstein et al, 1982). In
addition verapamil has been shown to compete with a variety of cytotoxic drugs,
associated with the MDR phenotype, for binding sites on P-glycoprotein
(Cornwell et al, 1987). Furthermore it has also been recognised that verapamil
can alter the phosphorylation state of P-glycoprotein (Hamada et al, 1987), which
may well modulate its function, and may even act as an alternative substrate for
the drug-efflux pump (Yusa & Tsuruo, 1989).
Although there are many studies confirming verapamil as an extremely effective
MDR modulator in vitro (Plumb et al, 1990) its use in patients has been limited
by cardiotoxicity manifest as severe hypotension and cardiac arrhythmias. This
has resulted in plasma concentrations 10-12 times lower than the most effective
for MDR modulation in vivo (Kerr et al, 1986) and has led to the search for
other effective MDR modulators which do not have such overt toxicity in vivo.
CALCIUM ANTAGONISTS
Other calcium antagonists apart fron verapamil have been shown to be effective
modulators of MDR in vitro including nifedipine and diltiazem (Tsuruo et al,
1983). More recently the tiapamil analogue N-(3,4-dimethoxtphenyl)-N-methyl-
2-(2-napthyl-m-dithane-2-propylamine) (DMDP) was shown to have a greater
resistance modifying effect, in doxorubicin-resistant P388 leukaemia cells, at half
the dosage level (Radel et al, 1988). Furthermore this study also demonstrated
that a 24 hour exposure to DMDP with a short exposure to doxorubicin resulted
in the same cytotoxicity as a 24 hour exposure to both agents suggesting that the
dosing schedule of potential modulators is extremely important.
CALMODULIN INHIBITORS
Calmodulin inhibitors such as trifluoperazine have been shown to potentiate the
cytotoxicity of doxorubicin in doxorubicin-resistant P388 leukaemia cells in vitro
(Ganapathi & Grabowski, 1983). The modulating effect appeared to be related
to increased intracellular accumulation of doxorubicin in resistant cells following
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exposure to trifluoperazine and furthermore this enhanced cytotoxicity did not
occur in the drug-sensitive parental line. More recently a range of calmodulin
antagonists were shown to be effective MDR modifiers in a colchicine-resistant
human KB carcinoma cell line with thioridazine having the greatest sensitizing
effect (Akiyama et al, 1986). However this study also demonstrated that not all
calmodulin inhibitors reversed MDR and suggested that the modulating effect
was not related to calmodulin inhibition. One possible explanation is that
calmodulin antagonists may interfere with lysosomal function since thioridazine
has been shown to delay the degradation of certain ligands within them
(Kuratami et al, 1986)
CYCLOSPORINS
The immunosuppressive drug cyclosporin A has been shown to modulate
resistance to daunorubicin and vincristine in acute lymphocytic leukaemia cells
in vitro (Slater et al, 1986a) and in Ehrlich ascites carcinoma cells in vivo (Slater
et al, 1986b). An important observation however has been that plasma levels of
cyclosporin A achievable in the clinic (1-2 pg/ml) are considerably lower than the
levels required for significant modulation in vitro (5 jag/ml) (Kahan et al, 1983).
This problem has been overcome to some extent by the use of non-
immunosuppressive cyclosporin analogues which are highly effective resistance
modulators at lower concentrations than cyclosporin A (Twentyman, 1988).
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OUINIDINE
Quinidine has been shown to be an effective modulator of MDR in vitro. In a
series of experiments quinidine increased vincristine and doxorubicin cytotoxicity
in the vincristine- and doxorubicin-resistant sublines of P388 leukaemia cells
(Tsuruo et al, 1984). Furthermore this enhanced cytotoxicity was associated with
increased intracellular accumulation of the respective drug. Once again the exact
nature of the mechanism which brings about MDR modulation is not known
although it may be due to a disturbance of the organisation of membrane lipids
(Surewicz & Jozwiak, 1983). One other possible factor which may contribute to
MDR modulation is a decrease in free intracellular calcium (Harrow & Dhalla,
1976). Although quinidine often has less modifying effect in vitro than the
calcium-channel blockers (Tsuruo et al, 1984) it has attracted much attention
because the levels required for modulation in vitro can be achieved in patients
plasma without adverse toxicity (Jones et al, 1990). It is therefore an ideal




In the light of contradictory data on MDR expression in breast cancer previously
described the first aim of this project was to confirm that the MDR product, P-
gp, could be detected in human breast cancers. The use of
immunohistochemistry, with specific monoclonal antibodies to P-gp, is a useful
tool not only to confirm P-gp expression but to examine the distribution of this
expression throughout the various cell populations present in breast cancers. By
deciding to look at expression in historical biopsy specimens it was hoped that
some conclusions could be reached regarding the relationship between P-gp
expression and certain pathological parameters as well as patient survival.
Having confirmed the presence of MDR expression in a proportion of human
breast cancers the next step was to see whether MDR could be circumvented in
drug-resistant breast cancer cells in vitro using a variety of modulators in
combination with anthracyclines. Potential modulators were assessed by their
effect either on chemosensitivity or intracellular cytotoxic drug concentration.
The second major aim was to establish an in vivo model of MDR so that known
in vitro modulators could be assessed to see whether P-gp was a relevant,
functional target in solid tumours. If this was the case then it would strengthen
the case for attempting to modulate MDR in human tumours known to express
P-gp ie. breast cancers. A natural progression from this work was to examine the
effect of one particular modulator, quinidine, on the concentration of epirubicin
in human breast cancers and its subcellular localisation. Finally the last chapter
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examines the hypothesis that the use of MDR modulators, in combination with
chemotherapeutic agents in patients, may lead to increased systemic toxicity.
In summary the work described in this thesis was designed to ascertain whether
one particular mechanism of cellular drug resistance, MDR, has any relevance
in the development of clinical drug resistance in human breast carcinoma and to
look at potential therapeutic manoeuvres to circumvent this problem.
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LAYOUT OF THESIS
Each chapter (2-7) is self-contained with an introduction, methods, results and
discussion section. Chapter 2 describes the expression of P-gp in human, primary
breast cancers and its distribution. Of particular interest was the finding of this
protein in stromal cells as well as malignant cells in these tumours. This stromal
cell immunostaining was confirmed as genuine expression of P-gp in Chapter 3
which also included an investigation of P-gp expression in normal breast tissue.
Chapter 4 concentrates on a comparison of the quinidine levels required for
modulation in vitro with tumour levels achieved in a human tumour xenograft.
Chapter 5 describes the establishment of a solid tumour model of MDR with
which to test the modulating capacity of several agents known to reverse MDR
cells in vitro. This provided encouraging results with two modulators and one of
these, quinidine, was used in an attempt to modulate MDR cells in human breast
cancers in Chapter 6.
Chapter 7 presents the toxicity data from a current phase III clinical trial which
was set up to examine the effect of oral quinidine on the response to
chemotherapy with epirubicin in patients with locally advanced or metastatic
breast cancer. The final conclusions of this work are presented in Chapter 8.
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CHAPTER 2
IMMUNOHISTOCHEMICAL DETECTION OF P-GLYCOPROTEIN
EXPRESSION IN PRIMARY BREAST CANCER AND
CLINICAL/PATHOLOGICAL CORRELATION.
INTRODUCTION
As mentioned in the general introduction previous studies of MDR expression
in breast cancer specimens have provided conflicting evidence about the presence
of P-gp in these tumours. Since the lack of agreement seems more apparent at
the mdr-1 mRNA level, with one study describing no expression (Merkel et al,
1989) and another reporting expression in the majority of tumours (Keith et al,
1990), it was hoped that measurement of P-gp itself would provide a conclusive
answer.
IMMUNOCYTOCIIEMISTRY
Immunocytochemistry (ICC) allows the detection of tumour-associated antigens
by specific monoclonal antibodies. In its earliest form monoclonal antibodies,
conjugated to fluorochrome markers eg. fluoroscein, were detected using a
fluorescence microscope (Coons & Kaplan, 1950). Although a relatively simple
technique, which detects antigens at low concentrations, it makes the
counterstaining and orientation of tissue constituents difficult and furthermore the
final preparations are not permanent.
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The use of immunofluorescence has now largely been superceded by
immunohistochemistry where enzymes eg horseradish peroxidase (Nakane &
Pierce, 1966) or alkaline phosphatase are used to produce intensely coloured,
permanent precipitates which can be viewed with a conventional light microscope.
Although the increase from a two-stage process (immunofluorescence) to a three-
stage process (immunohistochemistry) theoretically increases the risk of non¬
specific binding this is not normally a problem in practice if optimal dilutions of
antibodies are used. Several monoclonal antibodies to P-gp are now available
allowing detection by ICC.
One such antibody C219, which reacts with an epitope on the cytoplasmic side
of the P-gp molecule (Kartner et al, 1985), has been used to demonstrate P-gp
expression in both untreated and treated breast cancers (Salmon et al, 1989;
Schneider et al, 1989). In addition MRK16, which reacts with an external epitope
on P-gp, has been used to detect P-gp expression by ICC in untreated breast
cancer (Sugawara et al,1988).
The use of ICC appears to have several advantages when compared with other
techniques. The detection of mdr-1 mRNA in a homogenised tumour sample
gives no information as to which cells express the gene or how these cells are
distributed within a particular tumour. In addition it may not be sensitive enough
to detect a small population of MDR-positive cells. Immunocytochemical
techniques can circumvent these problems by allowing detection in single, or




In certain tumour types eg leukaemia it is feasible to obtain repeat tissue samples
for comparison, either before and after treatment or during the course of
treatment, in order to ascertain whether P-gp expression is related to any clinical
parameters. Since it is known that P-gp can be induced in vitro by exposure of
cells to a cytotoxic drug it is possible that P-gp is induced during treatment with
MDR-related drugs. This would result in failure to respond to a second course
of treatment with the same drug. Unfortunately sequential sampling is not
usually possible in breast cancer due to either complete excision of the original
tumour or the inaccessability of metastatic sites other than skin. Moreover the
long natural history of breast cancer means that relapse material for comparison
with the primary tumour may not be available for many years following the initial
presentation (Brinkley & Ilaybittle, 1984).
One way to overcome this problem and to address the question of the clinical
significance of P-gp in breast cancer is to examine historical biopsy material
collected several years previously and stored in tissue banks at -70°C. In this way
P-gp expression can be related to the clinical outcome of these patients. Of
course, any attempt to correlate P-gp expression with survival of the patient
makes the assumption that this particular mechanism of resistance in some way
contributes substantially to the overall resistance of the tumour, either to
conventional treatment or to anti-tumour host defence mechanisms.
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The study described in this chapter was therefore designed with several aims in
mind. The first priority was to attempt to confirm P-gp expression in human
primary breast cancer and if present to establish which cells express it and to
look at their distribution within the tumour. By examining P-gp expression in
historical biopsy material it was possible to look for any correlation with various
pathological parameters as well as the clinical outcome of the individual patients.
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MATERIALS AND METHODS
PATIENTS. HUMAN TISSUE AND CELL LINES
All twenty-nine breast cancer specimens were collected from patients undergoing
breast surgery at the University Department of Surgery, Royal Infirmary, Glasgow
during the years 1984-1986. The mean age of the patients, from whom biopsies
were collected, was 63 (range 36-89). Of 21 informative patients 11 were
oestrogen receptor positive and 10 were oestrogen receptor negative. None of
these patients had pre-operative chemotherapy although 6 had adjuvant post¬
operative chemotherapy with either cyclophosphamide, methotrexate and 5-
fluorouracil, CMF (n=3) or 5-fluorouracil, epirubicin and cyclophosphamide,
FEC (n = 3). All biopsies had been snap frozen in liquid nitrogen and stored at
-70°C until sectioning.
As a positive control for each group of specimens cytospin preparations of the
small cell carcinoma of lung cell line H69LX10, previously shown to have high
expression of P-gp (Plumb et al, 1990), were used. This continuous cell line was
derived from the parent cell line NCI H69 by chronic exposure to doxorubicin (to
a final concentration of 1 }xg ml"1) and was a kind gift from Dr P Twentyman
(MRC Clinical Oncology and Therapeutics Unit, Cambridge). H69LX10 was
maintained in Roswell Park Memorial Institute 1640 (RPMI 1640) medium
supplemented with 10% foetal calf serum (FCS), sodium bicarbonate and
L-glutamine (2pM). The cell line was grown in the presence of doxorubicin
(ljug/ml) to maintain its multidrug resistant phenotype.
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Cell suspensions of H69LX10 were centrifuged at 200g for five minutes and then
resuspended in phosphate-buffered solution (PBS). Aliquots (0.5ml) of this cell
suspension were then pelleted onto clean glass microscope slides in a cytospin
centrifuge (Shandon). These cytospin preparations were then fixed as for tissue
sections.
MONOCLONAL ANTIBODIES
For the detection of P-gp C219 (CIS UK Ltd, High Wycombe, Bucks)and MRK16
(donated by T Tsuruo, Institute of Applied Microbiology, University of Tokyo,
Japan) were used, both at a final concentration of 10 ,ug ml'1. This concentration
was found to be the optimal dilution over the range ljugml"1 - 20Qugmr1 by
immunostaining cytospin preparations of the cell line H69 LX10.
Selected cases were also stained using CAM 5.2 (Becton Dickinson, California,
USA), AE1/AE3 (ICN, High Wycombe, Bucks) to detect cytokeratins and with
antibody to vimentin (Boehringer, Lewes, East Sussex). The use of these
antibodies helps to differentiate epithelial cells (tumour cells) from other cells
which are derived from mesenchymal tissue eg. stromal fibroblasts. In negative
controls an irrelevant monoclonal antibody (Clonab LN-C, Biotest, UK) was
substituted for the primary antibody.
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IMMUNOCYTOCHEMISTRY
Cryostat sections 5pm thick were cut from each frozen biopsy, air dried for one
hour, then fixed in acetone at room temperature. After washing in Tris saline
(pH 7.6, 5 minutes) the sections were stained using an indirect immuno-alkaline
phosphatase technique (Figure 1), incubating sections with specific primary mouse
monoclonal antibodies for two hours. This and all subsequent incubations were
carried out at room temperature in a humidified container. All antibody
dilutions were carried out in Tris buffer (pH 7.6)
After washing in Tris saline (5 minutes) the second antibody was applied. This
was a rabbit anti-mouse immunoglobulin conjugated to alkaline phosphatase
(Dako, High Wycombe, Bucks) and used at a working concentration of 1:20 in
50% normal human serum (filtered), 100 pi per slide for 45 minutes. Following
a further wash in Tris saline (5 minutes) the sections were incubated with
alkaline phosphate substrate solution, 100 pi per slide, for 30 minutes, producing
a red reaction in P-gp positive cells. After counter staining with Haemotoxylin
(15 seconds) the sections were submerged in Scott's Tap Water Substitute (20
seconds) before mounting in a water-based mounting medium.
ALKALINE PHOSPHATE SUBSTRATE SOLUTION
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2.5 mg Naphthal AS B1 phosphate (Sigma, Poole, England) was suspended in 1
drop of dimethyl formamide (Sigma), in vertical laminar flow conditions, for 20
seconds until the solution became clear (solution A). 2.5 mg Fast red TR salt
was then dissolved in Veronal Acetate buffer* (pH 9.2, 5mls) in a universal
container (solution B).





Stored at 4°C away from light.
Solutions A and B were added together. 100 pi of Levamisole (Sigma), which
blocks endogenous alkaline phosphatase activity, was then added and the final












Diagrammatic representation of the immuno-alkaline phosphatase method. In
this case the antigen (P-gp) is recognised by one of two mouse monoclonal
antibodies (C219 or MRK16) which in turn bind to a rabbit anti-mouse second
antibody conjugated to alkaline phosphatase (RAM-AP). This enzyme acts on the
substrate solution, producing a red precipitate in positive cells.
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ASSESSMENT OF P-GP EXPRESSION AND PATHOLOGICAL
PARAMETERS
All tumour sections were examined by an experienced pathologist (Dr JJ Going,
Department of Pathology, Royal Infirmary, Glasgow) and an estimation of the
percentage of cells showing positive staining was made. No attempt was made
to quantify the intensity of the staining as this can vary slightly between
experiments and cells were normally clearly positive or negative. An adjacent
section of each tumour biopsy was stained with Haematoxylin and Eosin (H &
E) to confirm that tumour was present in the biopsy.
The same pathologist examined these H & E sections in order to assess the
overall grade (Elstron & Ellis grades I-III), the histological type (ductal, lobular
or medullary) and the presence of vascular invasion (positive or negative). The
extent of ipsilateral axillary node involvement (0,1-3,>4) was obtained from





Both C219 and MRK16 stained the positive control H69 LX10. Staining with
C219 (Figure 2a) was more intense than with MRK16 (Figure 3a) in this cell line
and in tumour frozen sections as well.
Twenty-nine breast cancers (all untreated) were incubated with C219 and MRK16
and the results from all patients are summarised in Table 1. C219 revealed a
heterogeneous pattern of staining in epithelial cells (Figure 2b) in 21 of 29
tumours. However, in 26 of the patients C219 showed marked staining in stromal
cells (Figure 2c). Furthermore, the proportion of positively stained stromal cells
was notably higher than that for the epithelial cells. Although the number of
cells staining with MRK16 was less than than with C219, the same pattern was
observed with expression in both epithelial (16 of 29) and stromal (12 of 29) cells
(Figures 3b,c). Immunostaining of epithelial cells, with both antibodies, occurred
in either single cells (Figure 2d) or occasionally groups of cells (Figure 3b). In
the presence of irrelevant antibody (Clonab LN-C) no areas of staining at all
were visible (Figure 3d).
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NUMBER OF PATIENTS
Epithelial Cells Stromal Cells
Proportion of cells
stained positive(%) C219 MRK16 C219 MRK16
0 8 13 3 17
1-9 17 14 1 9
10-49 4 2 10 2
50-100 0 0 15 1
TABLE 1
The number of patients allocated to each group according to the percentage of
positively stained cells, both epithelial and stromal, with two monoclonal
antibodies C219 and MRK16.
The stromal cells which were P-gp positive, with either C219 or MRK16, were
spindle-shaped cells with elongated nuclei (see Figure 2c and 3c). These cells
were confirmed as non-epithelial by positive staining with a monoclonal antibody
against vimentin (Figure 4a), an intermediate filament protein present in cells of
mesenchymal origin, and the absence of staining when incubated with the anti-
cytokeratin Cam 5.2 (Figure 4b), a monoclonal antibody which reacts with most
adenocarcinomas. Furthermore, no staining of stromal cells was observed with







Cytospin preparation of the MDR cell line H69LX10 stained with the monoclonal
antibody to P-glycoprotein, C219 (a). Plates b and c show heterogeneous staining,
again with C219, in both tumour (b) and stromal (c) cells in a section of a
primary breast cancer. Staining with C219 in an isolated tumour cell is also
shown (d).
FIGURE 3
Cytospin preparation of the MDR cell line H69LX10 stained with the monoclonal
antibody to P-glycoprotein, MRK16 (a). In sections of primary breast cancers this
antibody stained both tumour (b) and stromal (c) cells. Substitution of
MRK16 by an irrelevant antibody produced no areas of staining in sections of a




A section of primary breast cancer stained with antibody to vimentin (a) showing
staining of stromal cells with this antibody. The other two figures shows the same
section stained with the anti-cytokeratins Cam 5.2 (b) and AE1/3 (c) highlighting
the absence of staining in the same stromal cells.
32
CORRELATION OF P-GP EXPRESSION WITH PATHOLOGICAL
PARAMETERS AND DISEASE-FREE SURVIVAL
There was a total of twenty-seven informative patients from twenty-nine tumour
biopsy specimens. As would be expected ipsilateral axillary nodal status predicted
prognosis in terms of patient survival (20 patients, Table 2)
NODES ALIVE DEAD % SURVIVAL
0 6 2 75
1-3 5 3 63
>4 2 2 50
TABLE 2
The relationship between ipsilateral axillary nodal status and survival with a
median follow up of 34 months.
As results of immunostaining with both antibodies were comparable, and the
range of stromal staining was much greater with C219 (0-90%) than MRK16 (0-
50%), it was decided to use the C219 results to assess any possible association
between expression and the various pathological parameters and disease-free
survival.
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Immunostaining with C219, of epithelial or stromal cells, showed no correlation
with the histological type of tumour, tumour grade or the number of involved
ipsilateral axillary lymph nodes. In addition there was no correlation of P-gp
positivity with either oestrogen receptor status or the presence of vascular
invasion (Kruskal Wallace ranking test, Table 3).
Disease-free survival was assessed (median follow-up 34 months) using a Log
Rank test with tumours allocated to one of three groups according to the
percentage of P-gp positive epithelial cells (Gpl:0%, Gp2: <5%, Gp3: >5%). The
results, from twenty-seven patients, suggest that patients in Group 3 ( >5% of
epithelial cells) have a worse disease-free survival than the other two groups
(p = 0.09; Figure 5). In contrast P-gp positivity in stromal cells showed no
association with survival status (Figure 6).
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NUMBER OF PATIENTS



















The relationship between P-glycoprotein expression, detected by
immunohistochemistrywith C219, and the following parameters: tumour histology,
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The disease-free survival according to P-glycoprotein expression in epithelial





























■ P-gp pos (>50% stromal cells) (n-10)
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This disease-free survival according to P-glycoprotein expression in stromal cells,




This study has examined P-gp expression by immunohistochemistry in twenty-
nine primary breast cancers (all untreated) using two monoclonal antibodies
(C219 and MRK16) and an indirect alkaline phosphatase method. The results
clearly show that P-gp immunoreactivity, detected by C219 and MRK16, can be
demonstrated in a proportion of untreated primary breast cancers.
Immunostaining was heterogeneous and interestingly appeared in epithelial and
non-epithelial cells (Figure 2 & 3). It was confirmed that these non-epithelial
cells were of mesenchymal origin, by immunostaining with antibody to vimentin
(Figure 4a), and they are thought to be myofibroblasts.
Positive staining in epithelial cells with both C219 (21 of 29) and MRK16 (16 of
29) was detected in 1-9% of tumour cells in all but one tumour. This confirms
two previous studies which found P-gp expression in one of nine (Sugawara et al,
1988) and two of twelve (Schneider et al, 1989) untreated breast cancers. The
latter study considered staining in isolated cells to be negative, but it may be
these cells which are selected following drug exposure, and are responsible for
the development of clinical drug resistance. The staining in epithelial cells was
mostly membrane bound, although cytoplasmic staining was seen, and these cells
were confirmed as tumour cells by haemotoxylin and eosin staining of a separate
section from each tumour.
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A surprising finding was the demonstration of P-gp immunoreactivity in stromal
cells with both C219 (26 of 29)and MRK16 (12 of 29). The fact that stromal
staining has been detected by two monoclonal antibodies (Figures 2c & 3c),
which recognise different epitopes of P-gp, suggests that it is genuine expression
of the protein. This study provided the first published evidence of P-gp
expression in breast cancer stromal cells (Wishart et al, 1990a) although it is
known that one other group has detected expression in breast cancer stromal cells
by in situ hybridisation (Fojo, personal communication) and P-gp positive
macrophages have been detected in both lymphoid and non-lymphoid tumours
(Schlaifer et al, 1990). Since in situ hybridisation detects mdr-1 mRNA this
evidence argues against the possibility that the detection of P-gp in stromal cells
is due to a cross-reaction with some other cellular constituent. It has probably
not been recognised previously as other studies have often used human breast
cancer cell lines (Fairchild et al, 1987) or cytospin preparations of breast cancer
cell suspensions (Salmon et al, 1989) to study P-gp expression.
In all but one tumour the percentage of stromal cells staining was always greater
with C219 than with MRK16 (Table 1). Recent data from one study has
suggested that C219 may partially cross-react with the heavy chain of myosin in
skeletal and cardiac muscle (Thiebaut et al, 1989). Since it is well recognised
that scirrhous carcinomas of the breast contain a population of stromal cell with
characteristics ofmyofibroblasts (Tremblay et al, 1979), and that explants of these
cancers give rise to outgrowths of which >_90% are myofibroblasts (Barsky et al,
1984), it was conceivable that the higher results with C219 were due to a partial
cross-reaction with myosin. A more likely explanation, however, is that C219
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recognises an additional isoform of P-gp not detected by MRK16. This has
become apparent from a recent study which examined the expression of the three
hamster P-gp isoforms using isoform-specific antibodies in a competitive
immunohistochemical assay (Bradley et al, 1990). They found that the strong
staining of cardiac muscle fibres and a subset of skeletal muscle fibres was due
to expression of P-gp class III in these cells, an isoform not detected by MRK16,
and therefore not due to a cross-reaction with the muscle component of muscle
fibres. Furthermore examination of the amino acid sequences of myosin by
Bradley et al (1990) did not reveal a sequence that could be recognised by C219.
Previous studies with MRK16 have used formaldehyde fixation before
immuncytochemistry, as cells fixed with acetone showed only weak localisation
(Thiebaut et al, 1987). It could be argued that this is one reason why the positive
staining was usually less with MRK16 in both epithelial and stromal cells.
However, formaldehyde fixation with MRK16, when compared with acetone
fixation with the same antibody, did not increase the sensitivity of the
immunostaining in this study. This highlights the benefit of using a sensitive
method of P-gp detection, the immuno-alkaline phosphatase method being
particularly sensitive when compared to other immunohistochemical techniques.
The use of immunohistochemistry has not only allowed confirmation of P-gp
expression in human breast cancer but has revealed a heterogeneous distribution
of expression. This technique, as a result of its sensitivity, can localise
immunoreactivity in small numbers of single cells, unlike measurement of mdr-
1 mRNA in whole tumours (Fojo et al, 1987), which is less sensitive and can give
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rise to erroneous results because of tumour cell heterogeneity or expression in
adjacent normal tissue. Furthermore, without this method of detection the
immunoreactivity in stromal cells, previously unreported in the literature, would
not have readily come to light.
These results suggest that this particular mechanism of resistance may be relevant
in the development of clinical drug resistance in breast cancer and if this is the
case then P-gp may provide a potential target for modulation using specific agents
known to circumvent MDR in vitro (see Chapter 4). The novel finding of P-gp
expression in breast cancer stromal cells raises interesting questions about the
role of these cells in the development of drug resistance and experiments in the
following chapter will attempt to address some of these questions.
P-GP EXPRESSION. PATHOLOGY AND DISEASE-FREE SURVIVAL
Despite much evidence that P-gp plays a functional role in the multidrug
resistance phenotype in vitro little is known about the contribution of this
molecule, when present, to the overall clinical drug resistance of most tumours
in vivo. The most striking evidence that P-gp may be clinically relevant in certain
tumours is described in a study of thirty cases of childhood sarcoma (Chan et al,
1990). P-gp expression, detected by a modified immunoperoxidase method,
predicted a significantly shorter relapse survival (p< 0.001) in chemotherapy-
treated patients as well as a significantly smaller probality of survival (p< 0.001).
The results from the study, described in this chapter, of twenty-six informative
patients with primary breast cancer suggest that those patients with the highest
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levels of P-gp expression (>5% of tumour cells) have a worse prognosis in terms
of disease-free survival. Although these results do not reach statistical
significance and the numbers are small they nevertheless suggest a trend which
will require further investigation. In contrast P-gp expression in stromal cells was
not predictive for a worse disease-free survival. The results for epithelial
expression are consistent with two recently published studies which examined P-
gp expression by immunohistochemistry in locally advanced breast cancer.
In one series tumour samples from forty patients were obtained at mastectomy
following three courses of chemotherapy with doxorubicin, cyclophosphamide,
vincristine and prednisone. P-gp expression was observed in twenty patients
(<5% - >30% of tumour cells) with expression significantly greater in tumours
which showed a poor response to chemotherapy. Furthermore eight tumour
specimens obtained prior to chemotherapy, which were all P-gp negative, had a
complete response to chemotherapy. (Ro et al, 1990). The second study showed
that seven of seventeen patients with non-metastatic breast cancer, who had
intense staining in the majority of tumour cells, had a significant association
between P-gp expression and both response to chemotherapy and the time to
disease recurrence (Verelle et al, 1991). The latter study used a semiquantitative
scoring system that considered the intensity of staining as well as the number of
positive cells. The intensity of staining, however, can vary from batch to batch
of tumours and can be influenced by several factors ie. the intensity of
counterstaining and observer variation.
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Both these studies, which have suggested that P-gp expression may be relevant
in breast cancer, could be explained by a poor response to chemotherapy in P-
gp positive patients. In contrast, however, none of the tumours described in this
chapter had been exposed to cytotoxic drugs prior to surgery and although six
patients received adjuvant post-operative chemotherapy P-gp expression did not
predict a worse survival within that subset. Of these six patients there were two
patients in each of the three groups, according to the percentage of p-gp
expression in epithelial cells (0%, <5%, >5%), and one in each group relapsed
prior to P-gp assessment.
Verrelle et al (1991) describe seven patients with >75% of tumour cells being
P-gp positive. These percentages are much higher than the results described in
this chapter and most published series but could be explained by the fact that all
the tumours in their study were locally advanced (Stage II-III) and aggressive
(Grade II & III). Indeed the poor prognosis associated with P-gp expression in
the series of patients with primary breast cancer in this Chapter is apparently
unrelated to clinical drug resistance. P-gp may in fact be a biological marker of
tumour aggressiveness and this factor would explain both a poor response to
chemotherapy and a worse survival.
This hypothesis is supported by a recent study of colonic carcinomas which
suggested that P-gp-positive invasive colon cancer cells have an increased
potential for dissemination (Weinstein et al, 1991). There was a significantly
greater incidence of vascular invasion and lymph node metastases in tumours
with P-gp-positive invasive cells when compared to the tumours with P-gp-
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negative invasive cells. If P-gp expression is associated with local tumour invasion
and dissemination then measurement of P-gp, together with other known
prognostic factors eg. c-erbB2 (Borresen et al, 1990) may help to identify patients
who may benefit from adjuvant treatment. Alternatively in locally advanced
breast cancer, where there appears to be an association between P-gp expression
and response to chemotherapy, measurement of this protein may help to identify
tumours with significant MDR expression so that MDR drugs eg. anthracyclines




CONFIRMATION OF P-GLYCOPROTEIN EXPRESSION IN BREAST CANCER
STROMAL CELLS
INTRODUCTION
THE INTERACTION OF EPITHELIAL AND STROMAL CELLS
"V
It is well recognised that there is a close relationship between the epithelial
(malignant) and stromal components of human breast carcinomas. Since stromal
cells have been shown to influence the growth of normal mammary epithelial cells
in culture, as well as carcinogenesis in the breast epithelium (Sakakura et al,
1981), their presence in invasive breast cancer may be important in the
proliferation and metastatic capacity of these cancers.
The presence of large numbers of myofibroblasts in schirrous carcinomas leads
to the characteristic clinical changes caused by contraction of these cells eg. an
indurated, irregular mass with retraction of the surrounding breast tissue and/or
skin (Tremblay, 1979). Their presence has raised some debate as to whether they
represent an enhanced host response to the tumour or whether they are an
inherent part of the tumour itself. The finding of P-glycoprotein (P-gp)
immunoreactivity in these stromal cells (see Chapter 2) is therefore worthy of
further investigation firstly to confirm that the immunostaining represents true
expression and secondly to attempt to identify how it may arise.
SECRETORY CAPACITY OF STROMAL CELLS
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The majority of stromal cells in breast cancers are thought to be myofibroblasts
(Barsky et al, 1984) which are known to function as secretory cells laying down
collagen in the extracellular matrix. The finding of P-gp in these cells is therefore
consistent with the finding of P-gp in cells which also have a secretory function eg.
on the apical surface of epithelial cells of pancreatic ducts, proximal kidney
tubules, gastrointestinal tract and the biliary canalicular surface of hepatocytes
(Thiebaut et al, 1987). It is further supported by recent evidence of mdr-1 mRNA
expression, detected by in situ hybridisation, in the zona glomerulosa and zona
reticularis of human adrenal cortical tumours (Harvie, personal communication).
These are thought to be the main sites of production and secretion of aldosterone
and glucocorticoids.
One recent study supports this secretory role of breast cancer stromal cells and
suggests that they may play an essential role in the propensity to induce tumour
invasion (Basset et al, 1990). This study reported the secretion of Stromelysin 3,
a metalloproteinase enzyme which can degrade extracellular matrix, by
breast cancer stromal cells and not by epithelial cells in the same tumour.
Furthermore Stromelysin-3 gene expression was restricted to stromal cells in close
proximity to the tumour cells. These findings, and the absence of expression in
intraduct disease, has led to the hypothesis that a diffusible factor secreted by
malignant epithelial cells may induce production and secretion of Stromelysin 3
by stromal cells. These results would support the suggestion that a group of
"activated" fibroblasts may exist in invasive breast cancers (van der Hoof, 1988)
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and their products may be important in tumour progression.
COMPETITIVE IMMUNOHISTOCHF.MICAL STAINING
The six amino acid epitope where the monoclonal antibody C219 binds to P-gp is
now known from a study of hamster P-gp (Bradley et al, 1990). By using
overlapping hexapeptides, which covered the entire cytoplasmic domain of P-gp,
in an ELISA test with C219 the exact locus was identified (Figure 7). The
discovery of this sequence, VQEALD, led to the synthesis of a 15 amino-acid
epitope-containing peptide which could abolish the immunostaining by C219 by
preincubating the antibody with the peptide (Bradley et al, 1990).
C 219 C 219
FIGURE 7
A schematic representation of the P-glycoprotein molecule showing the putatative
transmembrane sites (1-6 and l'-6'), the ATP-binding sites (A,B, and A',B') and
the aminoacid sequence detected by C219.
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The use of this peptide (WQEALDKARGGRTC) therefore can provide a more
specific negative control than either omission of the primary antibody or
substitution by an irrelevant antibody. Omission of the primary antibody is used
to detect staining due to non-specific binding of the second antibody and to detect
the activity of endogenous enzymes which could react with the substrate. The
peptide is used in the studies described in this chapter to confirm that the
immunoreactivity in breast cancer stromal cells, described in Chapter 2, represents
true expression of the protein and not a cross-reaction with some other antigen.
It is conceivable that breast cancer stromal cells may express P-gp either as a
normal secretory process, to secrete collagen and other proteins, or as a specific
part of the malignant phenotype releasing enzymes such as Stromelysin 3 into the
extracellular matrix. The experiments in this chapter were therefore designed to
try to address some of these questions.
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AIMS OF THE STUDY
The primary aim of the study was to try to confirm genuine P-gp expression in
stromal cells by the use of immunohistochemistry and competitive inhibition with
a specific epitope-containing peptide.
The second aim was to compare P-gp expression, detected by
immunohistochemistry with C219, in pairs of normal breast and breast cancer
specimens from the same patient. If absent from the stromal cell population of
normal breast tissue this would suggest that P-gp expression in breast cancer
stromal cells was a transformation that arises de novo and not an enhanced form




For confirmation of P-gp expression five primary breast cancers, from the study
described in Chapter 2, were selected because of the high incidence of P-gp
immunoreactivity in their stromal cells (Table 4)
Tumour specimens from nine patients undergoing mastectomy at the University
Department of Surgery, Western Infirmary, Glasgow were collected in theatre then
snap frozen in liquid Nitrogen for storage at -70°C. In the same patients a sample
of "normal" breast was taken from the periphery of the mastectomy specimen and
stored in a similar fashion until staining.
MONOCLONAL ANTIBODY AND BLOCKING PEPTIDE
For the detection of P-gp the monoclonal antibody C219 was used at a final
concentration of lOjug/ml (see Chapter 2 ).
A 15 amino acid peptide was used to block the epitope on P-gp where C219 binds.
This peptide (WQEALDKAREGRTC) was a kind gift from Dr Elias Georges
(Ontario Cancer Research Institute, Canada). The peptide was used at a final
concentration of 67QuM which represented a 1000 fold molar excess of peptide to
antibody when incubated with C219 at a working concentration of lQjug/ml.
Following incubation of peptide and antibody for one hour at room temperature
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they were applied to the sections and immunohistochemistry was then performed.
TMMIJNOHISTOCHEMISTRY
The indirect immuno-alkaline phosphatase method, exactly as described in Chapter
2, was used with the same positive control, the small cell carcinoma of lung line
H69LX10. Immunostaining of tumour specimens was carried out on 5pm sections
fixed in acetone at room temperature for ten minutes. When the peptide was used
two sections from each tumour were stained, one with C219 and one with C219
and peptide.
PERCENTAGE OF P-GP POSITIVE CELLS








The percentage of P-glycoprotein positive cells, either epithelial or stromal, in five
tumours selected for use in the competitive immunohistochemical study.
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RESULTS
EFFECT OF THE PEPTIDE ON C219 REACTIVITY
Incubation of the blocking peptide with C219, prior to immunostaining with an
indirect alkaline phosphatase technique, completely inhibited staining in the
multidrug resistant cell line II69LX10 (Figure 8a,b). When the same technique
was used in the five tumour specimens it produced good amelioration of the
immunostaining in the stromal cells (Figure 8c,d) but not to the same extent as in
the control cell line. However, the amount by which staining was reduced in the
stromal cells was the same as in the tumour cells (not shown).
COMPARISON OF C219 REACTIVITY WITH NORMAL AND TUMOUR
TISSUE FROM THE SAME PATIENT
Immunostaining of the nine tumour sections revealed P-gp expression in both
tumour (7/9) and stromal (7/9) cells with marked stromal staining (>50% of
stromal cells) in 3/9 patients. In contrast however there was no staining in the
stromal cells in any of the "normal" breast (Figure 9)and only some apical staining
was seen in ductal epithelial cells (Figure 9c) in 2/9 patients. The two patients
with expression in ductal cells of normal breast also had the tumours with the
highest percentage of stromal cells which were P-gp positive.
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FIGURE 8
Immunohistochemical detection of P-glycoprotein (P-gp) in the multidrug resistant
cell line H69/LX10 without a and with b blocking peptide. Immunostaining of
P-gp in stromal cells of a primary breast cancer with d and without c blocking
peptide.
FIGURE 9
Immunostaining of P-gp in stromal cells of a primary breast cancer a and "normal"
breast specimen from the same patient b. P-gp expression in the apical portion
of ductal epithelial cells in a normal breast specimen c.
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DISCUSSION
These results suggest that the immunoreactivity in breast cancer stromal cells,
detected by the monoclonal antibody C219, represents genuine expression of P-
gp. Although the staining was not abolished completely by the peptide blocking,
as found in the positive control cell line H69LX10, this degree of amelioration
would not be expected from a non-specific peptide. The use of a specific blocking
peptide therefore provides a more specific negative control than omission of the
primary antibody or substitution by an irrelevant antibody. In addition the
expression of P-gp by MRK16 (see Chapter 2), which binds to a quite different
epitope from C219, provides further confirmation of these findings.
These results are in keeping with recently published data which found P-gp
expression by immunocytochemistry, with both C219 and MRK16, in stromal
macrophages and endothelial cells in a variety of tumours (Schlaifer et al, 1990).
Furthermore a recent study has identified a 150,000 dalton transmembrane protein,
implicated in multidrug resistance, which is not P-gp and is also expressed in
breast cancer stromal cells as well as malignant cells (Hickson et al, 1991). It
remains to be established whether these transmembrane proteins in breast cancer
stromal cells are involved in the MDR phenotype or whether they have a separate
secretory function.
It has recently been established that P-gp is a small family of proteins with three
members (Class I,II and III) in rodents and two members (Class I and III) in
humans (Bradley et al, 1990). The Class III isoform, which is found in cardiac
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muscle and a subset of skeletal muscle fibres, is not involved in multidrug
resistance like the Class I isoform. The detection of P-gp by MRK16, which does
not detect the Class III isoform in muscle (Wishart et al, 1990b), as well as C219
suggests that the P-gp detected in breast cancer stromal cells is the Class I isoform.
Since the Class I isoform is present in many normal tissues including the liver and
intestine (Fojo et al, 1987) it was important to ascertain whether P-gp expression
was a feature of stromal cells in normal breast as well as breast cancers.
The finding of P-gp expression only in occasional ductal, epithelial cells, and not
in stromal cells in "normal" breast suggests that the stromal cell expression in
breast cancer is not an enhanced form of a normal mechanism. The stromal cells
in "normal" breast and breast cancer would therefore appear to be quite diferent
in certain respects. These results arc consistent with the suggestion that a group
of "activated" (Tremblay , 1979) or "abnormal" (Grey et al, 1989) fibroblasts may
exist in malignant breast tumours. The latter study found that a population of
fetal-like fibroblasts in breast cancers produce "migration stimulating factors", not
produced by adult fibroblasts, which may contribute to the pathogenesis of breast
cancer by interfering with the normal epithelial-mesenchymal interaction.
Furthermore this group have demonstrated a fetal-like migratory phenotype of
skin fibroblasts in approximately 90% of patients with familial breast cancer and
50% of clinically unaffected first degree relatives of these patients (Flaggie et al,
1987). The latter observation implies that some genetic abnormality may lead to
the development of a migratory phenotype in fibroblasts in patients with breast
cancer.
It is well known that breast cancer fibroblasts can release a variety of proteolytic
enzymes,which can break down extracellular matrix, including elastase, cathepsins
and metalloproteinase (van der Hoof, 1988). There has been much debate as to
whether the breakdown of extracellular matrix by fibroblast products is important
in initiating tumours to metastasize. The finding of the Stromelysin 3 gene in
invasive breast cancer stromal cells in close proximity to malignant cells (Basset
et al, 1990) not only implicates these cells in the ability to metastasize but also
raises the possibility of a close interaction between both stromal and malignant
cells, possibly by the secretion of growth factors. The finding of P-gp expression
in breast cancer stromal cells may have a secretory role in the "activated"
fibroblast described by Tremblay (1979) or it may have a role in MDR not yet
established. Whether this expression arises as a drug-resistant mechanism or not
the presence of P-gp in breast cancer stromal cells may well interfere with current
chemotherapeutic regimens. It is possible that P-gp may actually be involved in
the secretion of some of these products in breast tumours. If this is the case then
these "activated" stromal cells, or the external factors which stimulate them, may
themselves become specific targets for anti-cancer therapy.
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CHAPTER FOUR
CHARACTERISATION OF OUINIDINE AS A RESISTANCE MODULATORWITH
POTENTIAL FOR USE IN VIVO
INTRODUCTION
A greater understanding of the cellular mechanisms which underly the development
of multidrug resistance (MDR) has raised hopes that this particular mechanism of
resistance may be a suitable target for circumvention. Development of MDR is
often associated with expression of P-glycoprotein (P-gp). This protein is thought
to act as an energy-dependent drug efflux pump (Chen et al, 1986) such that
resistant cells maintain a much lower drug concentration than their drug-sensitive
counterparts (Kessel, 1968). The results presented in Chapter 2 show that P-gp is
expressed in the majority of 29 previously untreated breast cancers. This protein,
therefore, would seem an appropriate target for MDR modulation in vitro and
potentially in vivo.
Further evidence that P-gp plays a functional role as a cytotoxic drug efflux pump
is its ability to bind some of the drugs involved in the MDR phenotype eg.
vinblastine (Cornwell et al, 1986). Cornwell and colleagues showed that
photoaffinity labelling of two vinblastine analogues to P-gp was inhibited by
vinblastine and vincristine but not actinomycin D, all drugs associated with the MDR
phenotype. The fact that not all MDR drugs compete for the specific vinblastine-
binding sites has led to the suggestion of the existence of more than one drug
binding site on P-gp.
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An important observation, however, is the ability of certain non-cytotoxic drugs eg.
quinidine and verapamil, which have been shown to overcome MDR in vitro, to
compete for these binding sites (Cornwell et al, 1987). A number of other
membrane-active compounds have also been shown to partially reverse multidrug
resistance in vitro including nifedipine (Tsuruo et al, 1983), calmodulin inhibitors
eg. trifluoperazine (Ganapathi ct al, 1983), cyclosporin (Twentyman et al, 1987) and
also amiodarone (Chauffert et al, 1987). It is not certain how all of these
modulators bring about reversal of MDR in vitro although it is known that verapamil
causes a significant increase in phosphorylation of the P-gp molecule (Hamada et al,
1987) and may actually act as a competitive substrate for P-glycoprotein (Horton et
al, 1989).
Although there are many compounds which do circumvent MDR in vitro their
clinical potential is often limited by the inability to achieve plasma levels, adequate
for MDR modulation in vitro, which do not cause adverse toxicity. As a result of
dose-limiting hypotension and heart block in patients with ovarian cancer (Ozols et
al, 1987) the plasma levels of verapamil achieved without toxicity are several fold
lower than the most effective concentration in vitro (Kerr et al, 1986). Verapamil
therefore has limited clinical use and attempts are now being made to identify
compounds which are as potent MDR modulators as verapamil but which do not
have the same patient toxicity.
Quinidine (6'-Methoxycinchonine), a well recognised MDR modulator in vitro
(Tsuruo et al, 1984), has been used for a number of years as an anti-arrhythmic
agent in patients (Mason et al, 1977) raising hope that it may have potential as an
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in vivo MDR modifier if quinidine levels adequate for MDR modulation in vitro can
be achieved without patient toxicity. Despite the recognition that quinidine (Figure
10) induces several functional changes in biological membranes the exact mechanism
underlying its therapeutic effect is not known although it has been suggested that an




The molecular structure of quinidine (6'-methoxycinchonine).
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A pilot study of quinidine, combined with epirubicin in the treatment of advanced
breast cancer, has shown that a mean steady state plasma level of 5.6juM can be
achieved following a four day course of oral quinidine (250mg twice daily) with
minimal toxicity (Jones et al, 1990). Although symptoms of cinchonism (dizziness,
tinnitus, visual disturbance and vomiting) can occur at higher doses of quinidine
they are uncommon at this dose. This is encouraging since quinidine has been
shown to be as effective as verapamil in vitro on a mole per mole basis and the
maximum plasma levels of verapamil achievable are only about 1-2 juM.
One further problem encountered in attempting to modulate MDR in vivo is that
many of the circumventing agents are highly protein bound in plasma eg. quinidine
(Iven, 1977). In addition it has also been shown that the addition of exogenous
alpha-1 acid glycoprotein (AAG) can reverse the modulating effect of verapamil on
doxorubicin cytotoxicity in doxorubicin-resistant Chinese hamster ovary cells
(Chatterjee et al, 1990). Chatterjee's study concluded that in addition to a plasma
membrane site there may be an endosomal site of action of verapamil in MDR cells
suggesting that resistance modifiers may not be effective in patients with high plasma
levels of AAG. These results have raised some doubt that tumour levels of
modifiers may not be adequate for in vivo MDR modulation in patients.
Furthermore, with increased levels of the acute phase plasma protein alpha-1 acid
glycoprotein in many cancer patients (Snyder & Ashwell, 1971), which is known to
bind to other modifiers eg. verapamil (Piafsky et al, 1978), the free plasma quinidine
may be decreased even further.
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The aims of the study described in this chapter were firstly to characterise the MDR
modulatory activity of quinidine in vitro to confirm whether a concentration of 5.6^iM
represents the optimal concentration for modulation. The second aim was to
determine whether such quinidine concentrations could be achieved in tumours.
Ideally it would have been more appropriate to carry out a basic pharmacokinetic
study of quinidine, including plasma and tumour levels, in patients with breast
cancer. Clearly the number of patients required to establish a plasma time-course
of quinidine due to the wide variation in quinidine metabolism between patients
make such an approach unrealistic. The study was therefore carried out in a human
MDR xenograft model where multiple time-course experiments are possible and
there is less variation between animals. However, in addition paired samples of
plasma and tumour, for quinidine estimation, were obtained from three patients with
breast cancer.
In order to carry out this pharmacokinetic study of quinidine tumour levels in vivo
it was neccessary to have a readily usable method for the estimation of plasma and
tissue quinidine concentrations in the laboratory. This was therefore established
and was compared to the quinidine immunoassay used in the clinical study




The human breast carcinoma cell line, MCF7 ADR, was used as an in vitro model of
MDR. This cell line, which exhibits resistance to doxorubicin in vitro, was derived
from the drug sensitive parent cell line MCF7 by chronic exposure to doxorubicin.
Both cell lines were obtained from Dr K Cowan (National Cancer Institute,
Bethesda, USA).
The cells were maintained in RPMI 1640 (Northumbria Biologicals, Cramlington,
Northumberland, England) supplemented with glutamine 2mM (Gibco, Paisley,
Scotland), 10% fetal calf serum (Globepharm, Esher, Surrey, England) and sodium
bicarbonate. The resistant subline, MCF7ADR, was exposed to doxorubicin (IOjjM)
for 24 hours every six weeks and has been shown previously to express P-gp
(Fairchild et al, 1987).
HUMAN TUMOUR XENOGRAFT
The drug-resistant human ovarian carcinoma cell line 2780AD, known to express
P-gp (Sugawara et al, 1988), was obtained from Dr RF Ozols (National Cancer
Institute, Bethesda, USA). The cell line was maintained in RPMI 1640 culture
medium supplemented with glutamine 2mM (Gibco, Paisley, Scotland), 10% fetal
calf serum (Globepharm, Esher, Emgland) and insulin (0.25 units/ml). The
resistance of this line was maintained by growth in the presence of doxorubicin
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(2uM).
The 2780AD cell line was grown as a xenograft in female MF1 nunu athymic mice
by subcutaneous innoculation of approximately 106 cells in an injection volume of
0.5 ml PBS. Following establishment of the xenograft three weeks later the tumour
was passaged into a further fifteen mice and allowed to grow. The mice were kept
at a constant temperature using a twelve hour light/dark cycle with free access to
food and water.
HUMAN TUMOUR BIOPSIES
Three patients undergoing breast surgery at the University Department of Surgery,
Royal Infirmary, Glasgow were treated with oral quinidine bisulphate (Astra, Kings
Langley, England) 250mg twice daily for four days prior to surgery (total dose 2g)
to achieve a steady-state level. This study was carried with the approval of the local
Ethical Committee and with informed consent from the patients. Following excision
of the tumour, 3-4 hours following the last dose of quinidine, a representative sample
was snap frozen in liquid Nitrogen and stored at -70°C until assayed. In addition a




Three potential modulators of MDR were investigated: quinidine, verapamil and
tamoxifen (all Sigma Chemical Company, Poole, Dorset, England). Each modulator
was used at a final concentration of 6.6 juM, made up in RPMI 1640, and added to
the cells for 24 hours with the doxorubicin. In addition cells were also exposed to
epirubicin in combination with various concentrations of quinidine (3.3/iM, 6.6/iM
and 9.9jjM).
CYTOTOXICITY ASSAY
Drug sensitivity was determined by a tetrazolium dye based microtitration assay
(Plumb et al, 1989). The assay is based on the ability of live, but not dead, cells to
reduceatetrazoliumdye,3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide
(MTT), to produce a water-insoluble formazan product and the resulting colour
reaction can be quantified by an enzyme-linked immunoassay (ELISA) plate reader.
The system is rapid, economical and the optical quality of the formazan product
lends itself to automatic handling. Moreover, the results are comparable to more
time-consuming techniques eg. clonogenic assay (Plumb et al, 1989). Since the assay
is carried out in 96 well microtitre plates combinations of potential modulators and
drug concentrations can be used in the one experiment.
Cells were plated out in 200/il of medium at a concentration of 1000 cells per well
in nine 96 well microliter plates (Linbro; Flow Laboratories, Irvine, Scotland). The
first and last columns contained medium only. The plates were incubated for three
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days at 37°C in an atmosphere of 2% C02 in air to allow the cells to attach and
grow.
The medium was then removed from the wells and replaced with 200 pi of fresh
medium containing drug and modulator. Each modulator was added to three 96
well plates. Serial dilutions of eight different concentrations of cytotoxic drug were
made up in RPMI 1640 at twice the final concentration. These were then diluted
with either drug-free medium or medium containing modifier at twice the final
concentration prior to addition to the wells. Cells were exposed to either doxorubicin
or epirubicin, both at a top concentration of lO^M. Both drugs were supplied from
Farmitalia (St. Albans, England). The plates were incubated for 24 hours at 37°C
with drug and modulator after which the medium was then replaced with drug-free
medium. This medium was replaced on each of the next two days.
On the fourth day following drug exposure the cells were fed with 200 /il fresh
medium. 3 - (4,5 - Dimethylthiazol - 2 - yl) - 2,5 - diphenyl - tetrazolium bromide
(MTT; Sigma) was then added at a concentration of 5 mg/ml made up in phosphate
buffered saline, 50 jul per well. The plates were wrapped in aluminium foil and
incubated for 4 hours at 37 C. The medium and MTT were then removed from the
wells and the insoluble MTT formazan crystals dissolved in dimethyl sulphoxide
(DMSO), 200 pil per well. In addition 25 jul of Sorenson's glycine buffer (0.1M
glycine, 0.1M NaCl, equilibrated to pFI 10.5 with 0.1M NaOH) was added to each
well.
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The absorbance in each well was recorded in an ELISA plate reader (model 3550
microplate reader; Bio-rad Laboratories Ltd, Watford, England) at a wavelength of
570 nm. The first and last columns, which contained medium only, were used to
blank the plate reader.
Cytotoxicity was expressed in terms of the ID50 , that is the concentration of drug
which gave half the absorbance of the control untreated cells.
ESTIMATION OF INTRACELLULAR DRUG ACCUMULATION
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The breast carcinoma cell line MCF7ADR was again used as an in vitro model of
multidrug resistance. Doxorubicin uptake was measured in the presence of a range
of concentrations of quinidine.
Cells were grown in six well plates (Nunclon) for two days to give a final density
of approximately 106 cells per well. Following removal of the medium 4ml of fresh
medium was added to each well and the plates allowed to equilibrate at 37°C in an
atmosphere of 2% C02 in air. (14C) Doxorubicin and doxorubicin were added in 0.5
ml of medium and quinidine sulphate (Sigma, Poole, England) in 0.5 mis of medium
was added to the wells to give a final doxorubicin concentration of 1 ,uM and 0.01
uCi/ml. For comparison three concentrations of quinidine sulphate were used:
3.3pM, 6.6pM, and 9.^M at the five hour timepoint.
At specified times (30, 60, 120, 180, 240, 300 minutes) the plates were placed on
ice and the medium removed. The cells were washed twice with ice-cold phosphate-
buffered saline (PBS) and incubated with 0.5 mis trypsin/EDTA (0.25%/lmM) for
five minutes at 37°C. The contents of the wells were transferred to scintillation vials,
the wells washed with 0.5ml PBS and the wash added to the vials. Scintillation fluid
(10ml, Ecoscint fron National Diagnostics, Somerville, USA) was added to each vial
and the radioactivity determined in a Packard liquid scintillation counter (Canberra,
Packard, Pangbourne, England). Three wells were used for each timepoint and the




Non tumour-bearing MF1 nunu athymic mice were used for study. They were kept
at a constant temperature in a twelve hour light/dark cycle with free access to food
and water.
DRUG ADMINISTRATION AND SAMPLING
Quinidine sulphate (Sigma, Poole, England) was dissolved in phosphate-buffered
solution (PBS) at a concentration of 7.5 mg/ml then filtered using a 0.22um
MILLEX-GS filter (Millipore, Molsheim, France). All mice were weighed and at
time 0 received a bolus intraperitoneal injection of quinidine 150 mg/kg. Three
mice were sacrificed at each time point (30 minutes, 1 hour, 2 hours, 3hours and 4
hours), blood collected by cardiac puncture and plasma stored at -20°C until assayed.
ESTIMATION OF TUMOUR OUINIDINE LEVEGS
Nude mice bearing the 2780AD xenograft (tumour volume approximately 2cm3)
were used for study. All mice were weighed, then given a bolus intraperitoneal
injection of quinidine sulphate 150mg/kg made up at a concentration of 3.75 mg/ml
in PBS. Two hours post injection the mice were sacrificed, blood was obtained by
cardiac puncture and plasma stored in 200ul aliquots at -20°C. In addition the




Total (protein-bound and unbound) plasma quinidine concentrations, in non tumour-
bearing mice, were measured using the EmitR assay kit (Syva UK, Maidenhead,
England), an enzyme-linked immunoassay based on competition between quinidine
in the sample and quinidine labelled with glucose-6-phosphate dehydrogenase (G6P-
DH) for antibody binding sites. Since G6P-DII activity decreases upon binding to
the antibody the sample quinidine can be measured in terms of enzyme activity. The
active G6P-DH converts nicotinamide adenine dinucleotide (NAD) to NAD-
hydrogenase (NADH) resulting in an absorbance change over a period of time that
is measured spectrophotometrically.
Aliquots (5Qui) of plasma samples were thawed prior to assay. Each sample was
diluted 1:6 with EmitR buffer (buffer) solution. A 50jul aliquot of this diluted sample
was again diluted 1:6 with the buffer. This was added to EmitR quinidine reagent
A (50ul/250pl buffer) and EmitR quinidine reagent B (50jul/25Qul buffer). The
absorbance of this sample was then immediately measured in a Perkin Elmer
spectrofluorophotometer at 340nm following calibration with known standard
quinidine concentrations. The results were calculated from the change in absorbance
over a thirty second time period.
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RMITr reagents




Reagent B : quinidine labelled with G6P-DH
pH 6.2
Buffer : 0.055mol/L Tris buffer
pH 8.0
All these products also contain 0.05% sodium azide.
I
FLUOROMETRIC ASSAY
The quinidine concentration of plasma and tumours was measured using a
spectrofluorophotometric technique which relies on the ability of quinidine to
fluoresce in an acid medium (excitation and emission wavelengths 350nm and 450nm
respectively). Measurement was carried out in a Shimadzu RF-540 recording
spectrofluorophotometer which compares samples to one standard of known
concentration.
The extraction was performed according to the original method of Cramer &
Isaakson (1963) with the modification that quinidine was extracted into n-heptane
instead of benzene (Iven, 1977). Plasma quinidine was extracted from a working
volume of 200ul murine plasma made up to 1ml with distilled water. Sodium
hydroxide (0.5ml 0.2N) and sodium chloride (0.5g) were added and the quinidine
extracted into 2.5ml n-heptane containing 3% isoamylalcohol (v/v). Sulphuric acid
(lml 0.1N) was added to 2ml of the organic phase (upper phase) and following
gentle shaking the fluorescence of the aqueous phase (lower phase) was measured
in the spectrofluorophotometer (see above). In addition a lml sample of human
plasma spiked with lOjug quinidine was used as a recovery control, to calculate the
extraction ratio, and a normal human plasma was used as a negative control. The
results are expressed in ;ug/mL
All tumour samples were homogenised in sulphuric acid (5ml, 0.1N) and each batch
processed included a spiked sample for estimation of recovery and a negative
control. The homogenates were added to sodium hydroxide (0.2ml 1.5N) containing
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0.5g sodium chloride and the extraction then proceeded as for plasma. The results
were corrected for the extraction of the recovery control and expressed in ^ig/g
tumour. In order to compare plasma and tumour levels lg of tumour was equated
to 1ml of plasma and a tumour/plasma extraction ratio calculated.
Quinidine was extracted from human plasma in exactly the same way as for murine
plasma except a working volume of 1ml undiluted human plasma was used.
Quinidine was extracted from human tumours exactly as for murine tumours.
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RESULTS
EFFECT OF OUINIDINE ON DOXORUBICIN AND EPIRUBICIN
CHEMOSENSITIVITY IN MCF7ADR CEIJLS
The sensitivity of MCF7ADR to doxorubicin is shown in Table 5. Also shown in this
table is the sensitivity of these cells when exposed to doxorubicin in the presence
of either quinidine (6.6pM), verapamil (6.bpM) or tamoxifen (6.6jjM). All three
modulators were similarly effective at a concentration of 6.6uM with a modulating
effect of 7-10.5 fold.
The combination of epirubicin and quinidine (6.6jiM) produces a much better
modulating effect (22.5-fold) than doxorubicin and quinidine (Table 6). In addition
quinidine , when used in combination with epirubicin, is an effective modulator over
the range 3.3-9.9pM. The effect of quinidine 9.9uM on sensitivity to epirubicin is
demonstrated in Figure 11.
EFFECT OF OUINIDINE ON INTRACELLULAR DOXORUBICIN
ACCUMULATION
The uptake of doxorubicin in MCF7ADR cells is much less than the drug sensitive
cell line MCF7. Quinidine increases the intracellular doxorubicin concentration
but not to the level of drug in MCF7 cells (Figure 12). Quinidine caused a very
small increase in doxorubicin accumulation in MCF7 cells.
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DRUG(S) ID50 (;iM) MODULATION
Dox 43.0 ±_ 2.31
Dox + Quin 6.17 +_ 1.46 7-fold
Dox + Ver 4.10 ±_0.62 10.5-fold
Dox + Tamox 5.30 + 2.36 8-fold
TABLE 5
The chemosensitivity, expressed as an ID50 of MCF7ADR cells to doxorubicin alone
and in combination with quinidine (quin), verapamil (ver) and tamoxifen (tamox),
all 6.6^iM.
DRUG(S) ID50 (^M) MODULATION
Epirubicin (E) 33.6 +.4.16
E + Q (3.3qM) 2.15 ±_ 1.23 15.5-fold
E + Q (6.6jiM) 1.50 +.0.17 22.5-fold
E + Q (9.9jiM) 0.67 ±_ 0.21 50-fold
TABLE 6
The chemosensitivity of MCF7ADR cells to Epirubicin (E) alone and in combination






Plot of absorbance versus the concentration of epirubicin in MCF7ADR cells exposed
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FIGURE 12
The effect of quinidine on the intracellular uptake of doxorubicin in MCF7 and
MCF7adr cells exposed to doxorubicin alone and in combination with quinidine
6.6/iM.
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PLASMA OUINIDINE TIME COURSE IN NON TIJMOUR-BEARING MICE
The results of plasma quinidine concentrations in non tumour-bearing mice following
an intraperitoneal injection of quinidine sulphate are shown in Figure 13. This
shows an exponential decrease of the initial high level following injection with
detectable levels still present four hours post injection.
FIGURE 13
Plasma quinidine concentrations (mean +_ SD) in MF1 nunu mice (non tumour
bearing) following a bolus intraperitoneal injection of quinidine sulphate 150mg/kg.
Each point represents the mean of three samples.
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OIJINIDINE ESTIMATION
The standard graphs of known quinidine concentrations versus arbitrary units
produced by the spectrofluorophotometer, when samples are compared to one known
quinidine concentration only, are shown in Figure 14a,b. This shows a linear
relationship, both at low (lOng/ml lOOOng/ml) and high (250ng/ml-10pg/ml)
concentrations confirming that quinidine concentrations can be calculated from
unknown samples when the spectrofluorophotometer is calibrated with one
concentration only (lOpg/ml). The technique was also validated in terms of
recovery, with a mean quinidine recovery of 88.2% (range 83.7-93.1%) in four spiked
human plasma samples, and reproducability with the error between samples being
<5%. In addition a comparison of this fluorometric assay with the immunoassay
provided results that were comparable.
COMPARISON OF PLASMA AND TUMOUR OUINIDINE LEVELS
Plasma and tumour quinidine concentrations in ten tumour bearing nude mice are
shown in Table 7. One plasma was lost during the extraction procedure due to a
breakage. The mean plasma quinidine concentration was 1.94 ug/ml (range: 0.21-
4.01). This represents a mean plasma concentration of 5.13 pM (range: 0.55-10.58).
The mean tumour concentration was 6.04 pg/g (range: 2.46-12.24 jug/g). The mean
tumour/plasma extraction ratio was 9.36 (range: 1.20-33.50). The recovery of the






Graphs showing linear relationship between quinidine concentration and arbitrary
units produced by the spectrofiuorophotometer, both at low (a) and high (b)




ANIMAL PLASMA PLASMA TUMOUR TUMOUR/PLASMA
(pM) (pg/ml) (jig/g) EXTRACTION RATIO
1 8.04 3.05 4.95 1.63
2 — — 12.24 —
3 4.20 1.59 2.46 1.55
4 4.30 1.63 8.95 5.49
5 10.58 4.01 5.87 1.46
6 9.11 3.45 5.53 1.60
7 7.93 3.01 3.61 1.20
8 0.55 0.21 7.04 33.50
9 0.62 0.24 6.21 26.40
10 0.82 0.31 3.55 11.45
TABLE 7
The results of plasma (pM & jig/ml) and tumour (pg/g) quinidine concentrations
in ten tumour bearing nude mice two hours following a bolus, intraperitoneal




Plasma and tumour quinidine concentrations in three patients undergoing surgery
for breast cancer are shown in Table 8. The mean plasma concentration was 1.48
pg/ml (range: 1.05-1.84 pg/ml). This represents a mean plasma concentration of
4.54 juM (range: 3.22-5.65 pM). The mean tumour concentration was 1.39 jug/g
(range: 1.25-1.46 jig/g). The mean tumour/plasma extraction ratio was 1.0 (range:
0.68-1.39). The recovery of quinidine was 99% (plasma) and 86% (tumour).
QUINIDINE CONCENTRATION
PATIENT PLASMA PLASMA TUMOUR TUMOUR/PLASMA
(pM) (pg/ml) (pg/g) EXTRACTION RATIO
1 3.22 1.05 1.46 1.39
2 4.76 1.55 1.45 0.93
3 5.65 1.84 1.25 0.68
TABLE 8
The plasma (pM & pg/ml) and tumour (pg/g) quinidine concentrations in three
patients with breast cancer pretreated with oral quinidine 250mg twice daily for
four days prior to surgery. The tumour/plasma extraction ratio is also shown.
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DISCUSSION
The results clearly show that MDR may be partly reversed in a P-gp positive human
breast carcinoma cell line (MCF7ADR) in vitro by the use of agents known to interact
with P-gp. The degree of modulation achieved with verapamil (10.5-fold), tamoxifen
(8-fold) and quinidine (7-fold) in combination with doxorubicin is of a similar
magnitude to previously published studies (Plumb et al, 1990; Ramu et al, 1984;
Tsuruo et al, 1984). Modulation with quinidine was dose-dependent over the range
3.3-9.9qM when used in combination with epirubicin. This demonstrates that
quinidine can be an effective in vitro MDR modulator even at a concentration less
than the optimal concentration (6-7pM) of verapamil required for MDR reversal in
vitro. Furthermore it is interesting to note that quinidine, when given in combination
with epirubicin, produced a much higher fold increase in sensitivity than with
doxorubicin. This observation has been noted elsewhere (Plumb, personal
communication) and indicates a significant difference between the interaction of
epirubicin and doxorubicin and P-gp. This is surprising in view of the similarity in
the structure of epirubicin and doxorubicin (Weenen et al, 1983) although it is well
documented that the cardiotoxicity of epirubicin is much less than that of
doxorubicin (Muggia & Green, 1991).
The results of the doxorubicin uptake study demonstrate that part of the increased
chemosensitivity in MCF7ADR cells, following exposure to quinidine, is due to
elevated intracellular drug concentrations. Although the amount of intracellular
doxorubicin could be increased approximately 2-fold by quinidine this was still much
less than intracellular drug level in MCF7 cells. It is difficult to understand how
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apparent 1-2 fold increases in intracellular drug concentration can effect large
increases (15-50 fold) in chemosensitivity. This may however be explained by recent
evidence which has suggested that modulation, as well as increasing the total amount
of intracellular drug, may also redistribute this drug within the cell (Schuurhuis et
al, 1989).
MOUSE OIJINIDINE PHARMACOKINETICS
Following intraperitoneal quinidine sulphate (150 mg/kg) plasma quinidine
concentrations of approximately 60pM were achievable 30 minutes post injection
in non tumour-bearing mice. Although quinidine was still detectable 4 hours post
injection there was a significant clearance of quinidine from the plasma within the
first two hours. Based on the assumption that clearance from plasma is related to
appearance of quinidine in tissues it was decided to use 2 hours as the time point
for simultaneous measurement of tumour and plasma quinidine concentrations.
Although this time was chosen empirically it was hoped that by two hours, when
quinidine concentrations were in excess of the levels required for MDR modulation
in vitro, the tumour levels would have reached a detectable level.
Two methods were used for the measurement of quinidine. The immunoassay, used
to measure plasma quinidine in non tumour-bearing mice, was not readily available
in the laboratory and it was therefore neccessary to establish a new assay for the
detailed pharmcokinetic study. As a result the fluorometric quinidine assay was
developed and this gave similar results to the immunoassay when plasma quinidine
samples were measured by both methods. The fluorometric assay was standardised
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over a range of concentrations of quinidine and was validated in terms of recovery
and reproducability with a small error between measurements. This assay involved
an organic extraction and this stage was found to be the most variable between
experiments. Thus the recovery figures quoted for human plasma appear greater
than that for mouse samples. However, provided recovery was assessed for each
batch of samples this problem was overcome.
The results of mean plasma (1.94jug/ml) and tumour (6.04pg/g) quinidine
concentrations in ten tumour-bearing mice following a bolus intaperitoneal injection
of quinidine sulphate (150mg/kg) gave extremely encouraging results. Not only was
the tumour quinidine detectable in all cases, the tumour/plasma extraction ratio was
greater than one at a time when the mean plasma quinidine concentration was 4.5
uM. Furthermore when plasma and tumour quinidine concentrations were measured
in three patients with breast cancer, who were pretreated with oral quinidine for four
days prior to surgery, these results were upheld with a mean tumour/plasma
extraction ratio of 1.0.
It is however notable that the extraction ratio for the mouse samples was much
greater than that for humans. This is possibly explained in part by the fact that the
protocol for quinidine administration differed in the two studies. However, it should
be noted that the human tumour xenograft was highly vascularised and thus the
measurement of tumour levels will include a significant quantity of plasma quinidine.
No attempt was made to estimate the blood volume of the tumour although this
would allow correction for this contamination. Since the vasculature was not
confined to the periphery of the tumour but penetrated throughout the tumour the
results can be interpreted as a high concentration of quinidine in close proximity
with the tumour cells. Clearly the vascular supply to human tumours varies greatly
depending on the tumour type and location and no animal model will correctly
reflect this pattern of vascularisation. Since it has already been shown that
doxorubicin can penetrate into breast tumours (Stallard et al, 1990) the xenograft
model used in this study is thought to be a fair comparison.
In conclusion the experiments described in this chapter confirm that quinidine is
an effective modulator of MDR in vitro and furthermore that quinidine levels
required for modulation in vitro can be achieved both in an animal model of MDR
but more importantly in human tumour biopsies. It is hoped that these results will
allay fears of inadequate tumour concentrations of quinidine, and other modulators,
due to high plasma protein binding (Iven, 1977) and increased levels of alpha-1 acid
glycoprotein in cancer patients (Snyder & Ashwell, 1971). An attempt to modulate
MDR with quinidine in the human tumour xenograft, which was based on these
encouraging results, is described in the next chapter.
CHAPTER 5
MODULATION OF MULTIDRUG RESISTANCE IN VIVO
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INTRODUCTION
There is now much evidence to support the theory that MDR can be reversed in
vitro by modulators which interact with P-gp. It is known that a wide range of
human tumours express P-gp (Fojo et al, 1987) but it is not known whether this
protein has a functional role in the development of clinical drug resistance. If P-
gp does act as a drug efflux pump in MDR cells in human tumours then it should
theoretically be possible to circumvent this function in vivo using modulators that
have been shown to work in vitro. Although there is much data supporting a reversal
of MDR in vitro there have been very few animal studies reported and this, together
with the lack of suitable modulators in patients, has meant there is much less
evidence suggesting that modulators have a therapeutic benefit in vivo.
In one of the few animal modulator studies published the calcium influx blocker,
nicardipine, was shown to enhance the cytotoxicity of vincristine in the treatment
of adult female mice innoculated intraperiteonally with a vincristine-resistant subline
of P388 leukaemia cells, P388/VCR (Tsuruo et al, 1983). This resulted in prolonged
survival in the groups treated with modulators when compared with those groups
treated with vincristine alone. Calcium influx blockers also enhanced the cytotoxicity
of doxorubicin in the treatment of the doxorubicin-resistant subline of the P388
leukaemia cells, P388/ADR. In contrast verapamil and a tiapamil analogue
(DMDP) failed to potentiate doxorubicin activity in mice innoculated with
doxorubicin-resistant P388 leukaemia cells (Radel et al, 1988). These studies
however are inconclusive with respect to the potential for MDR modulation in
patients since they are not solid tumour models and the drug and tumour are being
delivered to the same site. In effect the peritoneal cavity of the mice is being used
as tissue culture medium for the resistant cells . In one study where verapamil was
tested in a solid tumour model it was shown to partially reverse resistance to
vincristine in a human epidermoid lung cancer xenograft when given with vincristine
(Mattern et al, 1987). These differing results highlight the difficulty in establishing
a good animal model of MDR in which to test potential modulators with the timing,
route of administration, and dosage of both modulator and drug being extremely
important.
To date only two published series have suggested that MDR modulation may be of
benefit in MDR-positive human tumours. The first study involved six myeloma or
lymphoma patients who relapsed during treatment with vincristine, adriamycin and
dexamethasone (VAD). At relapse the addition of verapamil, given by continuous
intravenous infusion with each pulse of chemotherapy, to the VAD regime resulted
in an objective response in three of six (50%) patients with P-gp positive tumour cells
but no response in P-gp negative tumours (Dalton et al, 1989). A second study of
18 lymphoma patients, who had all failed to respond to a doxorubicin containing
regime, reported a 72% response rate when these patients were further treated with
cyclophosphamide, VAD, as well as a five day verapamil infusion (Miller et al, 1991).
In contrast to both these studies a phase I-II study failed to demonstrate a
potentiating effect for doxorubicin in eight drug resistant ovarian cancer patients
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(Ozols et al, 1987). However, P-gp expression was not documented in these
tumours. The dose-limiting toxicity of verapamil in both clinical studies was
transient cardiotoxicity, manifest as hypotension and heart block, which was
reversible on stopping the verapamil. This cardiotoxicity, which limits plasma levels
to between three and twelve times lower than the most effective concentration in
vitro (Kerr et al, 1986), is thought to be due to calcium antagonism, a function
separate and not neccessary for MDR modulation.
Current studies, therefore, are attempting to identify compounds which are effective
modulators of MDR, both in vitro and in vivo, but which do not cause unacceptable
toxicity in patients when administered in combination with chemotherapeutic agents.
Plasma levels of quinidine, which were shown to modulate MDR in vitro (see chapter
4), can be achieved in patients without adverse toxicity (Jones et al, 1990) suggesting
a possible role for this compound as an in vivo modulator. Furthermore, it was also
demonstrated that administration of quinidine to both mice and patients gave levels
in the tumour adequate for resistance modulation. Quinidine was therefore chosen
for a detailed investigation of the ability of resistance modulators to overcome drug
resistance in an animal model of MDR.
AIMS OF THE STUDY
Since human breast cancers are solid tumours, like many other human tumours
which acquire clinical drug resistance, it was neccessary to establish a solid tumour
animal model of MDR to test the potential modulator, quinidine. As discussed the
intraperitoneal models used by Tsuruo (1983) and Radel (1988) were not suitable.
Unfortunately the growth of breast cancer cell lines as xenografts in mice is
extremely difficult and requires hormonal manipulation and this would interfere with
any attempt to influence growth delay.
The multidrug resistant ovarian carcinoma cell line (2780AD) was already
established as a xenograft in the Department and this model was thus the obvious
choice for these studies. The study was designed to determine whether the
combination of a modulator with a cytotoxic drug could produce a significant tumour
growth delay. Three modulators were included in the study. Verapamil is an
effective modulator in vitro but it is thought that dose limiting toxicity prevents its
use in vivo. The assumption was, therefore, that this modulator would have little or
no activity. Quinidine had been identified as a modulator that was as effective as
verapamil in vitro but had the advantage that higher plasma levels could be achieved
both in animals and, more significantly, in patients. However, it was apparent that
even for quinidine these plasma levels were only just adequate. It was therefore
decided to include a modulator (RO11-2933) that is highly potent in vitro at only 2
juM, a concentration easily achieved in mice (Yin et al, 1989).
RO 11-2933 is a tiapamil analogue that has little activity as a calcium antagonist. It
is, therefore, not associated with the dose limiting toxicity of the calcium antagonists.
It has never been used in humans and therefore does not have the immediate
clinical interest associated with quinidine.
In the design of this study consideration was given to the amount of modulator used,
the timing of modulator and drug administration and the route of administration.
The amount of quinidine administered was aimed at the maximum tolerated dose
in mice on the basis that this was most likely to show an effect. The timing of
modulator administration is complicated therefore a simple regimen was used based
on quinidine pharmacokinetics (see Chapter 4) and assumptions about the length of
duration of activity of epirubicin ie. for several hours following administration. In
terms of administration of drugs the intraperitoneal route is the simplest where large
numbers of mice are involved but the cytotoxic drug was shown to be toxic via this
route so it was given intravenously eventually.
It was decided to use epirubicin since greater modulation with epirubicin than
doxorubicin has been demonstrated (see Chapter 4) and furthermore it is the
commonest single chemotherapeutic agent used in the treatment of advanced breast
cancer in the West of Scotland (Habeshaw et al, 1990). In addition a Phase III
placebo-controlled, double blind trial is currently ongoing, in the West of Scotland,
to assess the effect of oral quinidine on the response to chemotherapy with




The maintenance of the 2780AD cell line, the establishment of the subcutaneous
xenograft and the maintenance conditions of the mice are described in the "Materials
and Methods" section in Chapter 4.
TISSUE DISPOSITION OF EPIRUBICIN
Twenty-four tumour-bearing, female, athymic mice were weighed then randomised
to receive quinidine (Sigma, Poole, England) or no quinidine prior to treatment with
epirubicin (Farmitalia, St Albans, England). The quinidine treatment group were
given four doses of quinidine sulphate (136.8mg/kg) intraperitoneally at -26 hours, -
18 hours, -10 hours and -2 hours prior to epirubicin treatment to attempt to achieve
adequate levels for MDR modulation.
At 0 hours all mice were given an intravenous, bolus injection of epirubicin,
38mg/kg, via the tail vein. The dose of both epirubicin and quinidine was converted
for the mouse from human doses of 100mg/m2 and 500mg (total daily dose of
quinidine) respectively (Carter et al, 1977). At 1 and 4 hours following epirubicin
administration animals were anaesthetised with ether, and blood and organs
collected. A futher quinidine dose at + 6 hours was administered to the 12 hour post
treatment group before sacrifice.
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Heart, liver, small intestine, kidney, muscle and tumour tissue was stored at -70°C
prior to analysis for epirubicin levels at 1, 4 and 12 hours post epirubicin
administration. Plasma was stored at -20°C until assayed.
ESTIMATION OF EPIRUBICIN IN MOTJSR PLASMA AND TISSUES
All tissues were washed and weighed prior to homogenisation. A 1:10 tissue to
buffer homogenate was prepared by adding a nine-fold weight/volume (w/v) excess
of phosphate buffered saline. Epirubicin was extracted from 0.2ml to 1ml of
homogenised tissue pre-treated with silver nitrate (33% w/v, 200ul per ml
homogenate) by vortexing with chloroform-propanol (2:1). Daunorubicin was used
as an internal standard for estimation of the extraction efficiency. The organic phase
was evaporated to dryness and finally reconstituted in 0.1ml of methanol before
analysis by Pligh Pressure Liquid Chromotography (HPLC).
Chromatographic separation and quantification of epirubicin in tissues and plasma
was performed by reverse phase liquid chromotography on a 4mm x 25cm u-
bondpak C18 column. lOul injections of standards and unknown samples were
programmed to run at 15 minute intervals on a Milton Roy "Promis" autosampler.
Detection was by fluorescence (excitation 480nm, emission 560nm) and integration
of peak areas was performed on a JCL6000 chromatography data system.
94
GROWTH DELAY EXPERIMENT WITH INTRAPERITONEAL
ADMINISTRATION OF EPIRIJBICIN
The tumour had been passaged three times from implantation of cells into the mice
prior to this experiment and tumours were approximately 1.5 cm3 at the start of the
experiment.. Epirubicin (Farmitalia, St Albans, England) was made up at a
concentration of 1 mg/ml in distilled water.
TREATMENT SCHEDULE
10 tumour-bearing mice were weighed then randomly allocated to one of two groups:
Group 1 No treatment (n = 5)
Group 2 Epirubicin alone (n = 5)
Epirubicin was given as an IP bolus 10 mg/kg in an injection volume of 10 jil/g.
Tumour volume was measured by calipers using the following formula, where d =
the mean of two diameters in the horizontal plane.
VOLUME = n X d3
6
Measurements were made on day 0 (just prior to treatment), day 3, day 5 and day
7. In addition the mice were weighed at the same time.
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ANIMAL TOXICITY STUDIES
Mice bearing the 2780AD xenograft were used for study. A dose ranging experiment
was carried out in groups of four mice for each modulator. The dose intervals used
were lOmg/kg for verapamil (range 50-100mg/kg), 25mg/kg for quinidine (range
160-250mg/kg) and 20mg/kg for ROl 1-2933 (range 140-250mg/kg). LD50 and
LD10 values were derived from probit analysis of the data.
GROWTH DELAY WITH INTRAVENOUS ADMINISTRATION OF
EPIRIJBICIN IN COMBINATION WITH RESISTANCE MODULATORS
Epirubicin was given by an intravenous injection into the tail vein at the same dose
that was given intraperitoneally (10 mg/kg).
Tumour bearing mice were weighed then randomised to receive no treatment,
epirubicin alone, epirubicin and quinidine, epirubicin and verapamil or epirubicin
and ROl 1-2933. The modulators were given by bolus IP injection two hours prior
to and four hours following epirubicin at the following doses (number of animals in
parenthesis):
Quinidine 150 mg/kg (n = 6)
Verapamil 50 mg/kg (n = 6)
ROl 1-2933 30mg/kg (n = 6)
In addition to the three groups described above there were 6 mice in each of the two
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control (untreated and epirubicin alone) groups. The mice were weighed and the
tumours measured daily.
STATISTICS
The tumour volume of each mouse on days 3, 5 and 7 was compared to the pre-
treatment tumour volume and the difference expressed as a percentage of the initial
weight to correct for any differences in size between groups. This ratio was then
converted to a logarithmic function and the five study groups compared by analysis
of variance. Any significant differences were further analysed by pairwise group
comparison using Bonferoni P values.
ESTABLISHMENT OF THE XENOGRAFT CELL LINE IN CULTURE
A tumour was aseptically removed from a mouse. It was dissected into 1mm pieces
and incubated with collagenase (200units/ml; Boehringer, Lewes, England) in RPMI
1640 medium. After several days epithelial cells were removed by incubation for five
minutes at 37°C with 0.5ml trypsin/EDTA (0.25%/lmM). These cells were plated
out in 25cm3 flasks (Nunclon) and allowed to attach and grow. These cells were
used both for detection of P-gp and for assessment of drug sensitivity of the cells.
Cytospin preparations were made by spinning cells suspended in PBS onto clean
glass microscope slides in a cytospin centrifuge (Shandon). These were stained by
an immuno-alkaline phosphatase method using a specific antibody to P-gp, C219.
This method is fully described in Chapter 2.
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The protocol for the cytoxicity assay was described in Chapter 4 and was carried out
using the three modulators used in the study; Quinidine (6.6pM), Verapamil (6.6pM)
and RO11-2933 (6.6jiM).
CONFOCAL MICROSCOPY
By using a laser scan microscope in confocal mode "optical sectioning" can be carried
out at levels of focus which are spaced less than lpm apart thus eliminating out-
of-focus epifluorescence. Several images can then be superimposed to produce a
single, crisp image with a good depth of focus. This technique is therefore ideal for
examing the subcellular localisation of fluorescent drugs in tumour sections.
The intracellular distribution of epirubicin was studied in four of the 2780AD
xenografts, two from mice treated with epirubicin alone and two from mice treated
with epirubicin and quinidine. Quinidine (150mg/kg) was administered as an
intraperitoneal bolus two hours prior to intravenous epirubicin (lOmg/kg) given as
a bolus tail vein injection. The mice were sacrificed two hours post-epirubicin and
the tumours stored at -70°C until sectioning.
Tumour frozen sections 20pm thick were cut from the tumours and mounted without
fixation in Glycergel water-based medium (Dako, Fligh Wycombe, England). The
distribution of epirubicin was analysed on a Carl Zeiss laser scan microscope (LSM
10) by confocal microscopy with Argon laser excitation at 488nm. The sections were




EFFECT OF OUINIDINE ON EPIRUBICIN PLASMA. TISSUE AND TUMOUR
CONCENTRATIONS
The epirubicin concentrations ( mean +_ S.D.) in plasma, tissue and tumour at
specified times following an IP bolus of epirubicin 38 mg/kg are shown in Figures
15 & 16. Also shown are the epirubicin concentrations obtained when quinidine
(136.8mg/kg) was given by IP bolus prior to epirubicin. Although the one hour
plasma epirubicin concentration was reduced by the addition of quinidine this
decrease was not maintained and was not reflected in either increased tumour or
tissue epirubicin levels over this time course.
Tumour
Epirubicin concentration/time - Mean ± S.D
Hours
Plasma
Epirubicin concentration/time - Mean values ± S.D.
Hours
Muscle tissue
Epirubicin concentration - Mean values ± S D
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FIGURE 15 hours
Plasma, tumour and tissue epirubicin levels at 1, 4 and 12 hours following
intraperitoneal epirubicin (38mg/kg) alone and in mice pretreated with
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Tissue epirubicin levels at 1, 4 and 12 hours following intraperitoneal epirubicin
(38mg/kg) alone and in mice pretreated with quinidine 136.8mg/kg intraperitoneally
2 hours prior to epirubicin. Each time point represents the mean of three samples.
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EFFECT OF INTRAPERITONEAL ADMINISTRATION OF EPIRUBICIN ON
BODY WEIGHT
The untreated group maintained their body weight while the epirubicin-treated group
lost weight rapidly and became cachectic. The mean body weight of both groups,
expressed as a percentage of the initial weight, is shown in Figure 17.
TUMOUR VOLUME
Epirubicin had no effect on tumour growth. There was no significant difference
between groups in the mean change in tumour volume, expressed as a percentage
of the initial pretreatment tumour volume, on days 3, 5 or 7.
ANIMAL TOXIXITY STUDIES
The acute toxicity in tumour bearing mice of the three modulators is shown in Table
9. For verapamil and quinidine deaths were observed within the first hour after
administration of the drug. In contrast, no immediate toxicity was observed with










The mean body weight , expressed as a percentage of the pretreatment weight, in
2780AD tumour-bearing nude mice receiving the following treatment: Group 1, no
treatment; Group 2, intraperitoneal epirubicin (lOmg/kg).
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MODIFIER LD10 (mg/kg) LD50 (mg/kg)
VERAPAMIL 51 (32-81) 75 (62-92)
QUINIDINE 185 (164-207) 204 (191-219)
ROl 1-2933 152 (129-180) 180 (160-203)
TABLE 9
Acute toxicity of three modulators (verapamil, quinidine and ROl 1-2933) in mice
bearing the 2780AD xenograft. Drugs were administered intraperitoneally and 4
mice were used at each dose.
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EFFECT OF INTRAVENOUS ADMINISTRATION OF EPIRlJBICIN ON BODY
WEIGHT
All five groups, both treated and untreated, maintained or increased their body
weight and looked healthy during the period of study.
EFFECT OF INTRAVENOUS ADMINISTRATION OF EPIRUBICIN ON
TUMOUR GROWTH RATE AEONE AND IN COMBINATION WITH
RESISTANCE MODULATORS
The tumour doubling time was approximately two days (Figure 18). When groups
were compared according to the change in tumour volume between days 0-2, 0-5 and
0-7 significant differences were found at day 2 but not at days 5 or 7. Treatment
with epirubicin alone showed a slight, but not significant, growth delay when
compared to the untreated group. The addition of verapamil resulted in an
increased growth delay which again was not significant and resulted in two deaths
in this group, within the first 24 hours after drug treatment.
Addition of either quinidine or RO11-2933 caused a highly significant growth delay
when compared to the untreated group (p< 0.001) and the group treated with
epirubicin alone (p = 0.01). These findings are highlighted in Figure 19 which shows
the mean relative tumour volume in each group during days 1-7. Furthermore the
growth delay during days 0-2 is more apparent when the relative tumour volumes of
individual mice are plotted (Figure 20). This shows that mice treated with either
quinidine or RO-112933 show little tumour growth during days 0-2 when compared
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FIGURE 18
Tumour volume in mice bearing the 2780AD xenograft showing an approximate













The mean relative tumour volumes in 2780AD tumour bearing nude mice during
days 1-7 following treatment with the following drugs: Group 1, untreated; Group2,
epirubicin alone; Group3, epirubicin + verapamil; Group4, epirubicin + quinidine;
Group 5, epirubicin + RO-112933. Epirubicin (10 mg/kg) was given by tail vein
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FIGURE 20
The relative tumour volumes of individual mice bearing the 2780AD xenograft
following treatment following no treatment (Group 1) and treatment with epirubicin
alone (Group 2), epirubicin and quinidine (Group 4) and epirubicin and RO-112933
(Group 5). Epirubicin was given by tail vein injection and all three modulators were
given by intraperitoneal bolus 2 hours prior to epirubicin.
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EFFECT OF MODULATORS ON THE SENSITIVITY OF 2780AD
XENOGRAFT CELLS TO DOXORUBICIN
The ID50 for doxorubicin alone, and in combination with verapamil, quinidine and
ROll-2933 in the 2780AD cells derived from the xenograft (2780AD/XENO) are
shown in Table 10. For comparison the ID50 in 2780AD cells with doxorubicin ±_
verapamil is shown.
The 2780AD/XENO cells (ID50 = 295 Ji 2.9) were more sensitive to doxorubicin
than the 2780AD cells (ID50 = 7430+.920). Increased sensitivity to doxorubicin was
found with verapamil (10.9 fold), quinidine (4.2 fold) and RO-112933 (19.3 fold)




CELL LINE DOXORUBICIN VERAPAMIL QUINIDINE RO-112933
2780AD/ 295 +.2.9 27 ±_ 1.5 70^3.5 15.3 ±_ 0.9
XENO ( 10.9 ) ( 4.2 ) ( 19.3 )
2780AD 7430 ±. 920 790 30.0
(9.4)
TABLE 10
Chemosensitivity of 2780AD/XENO cells, expressed as an ID50 when exposed to
doxorubicin alone and in combination with verapamil, quinidine and RO11-2933.
For comparison the ID50 of 2780AD cells exposed to doxorubicin +_ verapamil,
again in an MTT assay, is shown.
DETECTION OF P-GLYCOPROTEIN
Immunohistochemical staining of cells derived from the 2780AD xenograft (control,
untreated group) after the completion of the studies revealed P-gp expression to be
present in the majority of cells (Figure 21a). The intensity of the staining in these
cells was less than in the 2780AD cells prior to establishment of the xenograft
(Figure 21b). Appropriate positive and negative controls were satisfactory (results
not shown).
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EFFECT OF OUINIDINE ON SUBCELLULAR LOCALISATION OF
EPIRUBICIN
Examination of sections from the 2780AD xenograft in mice treated with epirubicin
alone revealed both cytoplasmic and nuclear autofluorescence, often with intense
peri-nuclear localisation (Figure 22). In contrast those tumours treated with a
combination of epirubicin and quinidine had predominantly nuclear fluorescence and
the intensity was greater than the tumours exposed to epirubicin alone even with




Immunohistochemical staining of P-gp, using the monoclonal antibody C219, in cells
derived from the 2780AD xenograft (a) and in 2780AD cells prior to establishment




Upirubicin autofluorescence in 2780AD xenograft (a) showing both cytoplasmic and
nuclear fluorescence. When the 2780AD xenograft is exposed to epirubicin and
quinidine the fluorescence is predominantly nuclear (b) and is much more intense
even with the brightness of the laser reduced to approximately one fifth of (a).
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DISCUSSION
These results demonstrate a significant growth delay by the addition of either
quinidine or RO11-2933 to intravenous epirubicin in mice bearing a solid tumour
model that is resistant to epirubicin. This resistance to epirubicin was confirmed in
vivo since no growth delay in this tumour model was seen with epirubicin alone.
The use of verapamil did not improve the growth delay achievable with epirubicin.
Although there was no increased drug delivery to tumour cells, with the addition of
quinidine, there was a change in intracellular drug distribution which may account
for the improved response to epirubicin.
The resistance of the 2780AD xenograft to epirubicin was confirmed by the fact that
no growth delay was seen when the mice were treated with epirubicin alone. With
the addition of verapamil there was no effect even at the dose used (the LD10)
which was high enough to cause mice deaths from acute toxicity following injection
of verapamil. When epirubicin was used in combination with quinidine, at a dose
known to achieve tumour quinidine levels adequate for MDR modulation, there was
a significant growth delay when compared to the untreated group (p< 0.001) and the
group treated with epirubicin alone (p = 0.01). A similar result was achieved with the
modifier RO 11-2933 but this may have even more potential as an in vivo modulator
of MDR since this compound was not used at the maximum tolerated dose.
There are two pices of evidence which support the theory that the significant growth
delay is due to modulation of MDR in vivo. Firstly the tumour was shown to have
maintained expression of P-gp by immunohistochemical staining with the monoclonal
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antibody C219 in cells derived from one of the tumours. Secondly these same cells
could be modulated in vitro by agents known to reverse multidrug resistance.
A potential criticism of this study would be that the significant growth delay with
quinidine and RO11-2933 is not due to modulation of MDR at all. This criticism
can be easily answered by repeating this study in the drug-sensitive A2780 xenograft
and these studies are in progress. Another explanation for the growth delay is that
the modulators in some way altered the pharmacokinetics of epirubicin to favour
tumour drug delivery. Although an interaction has been described between
verapamil and doxorubicin (Kerr et al, 1986) the use of quinidine had no effect on
the delivery of epirubicin to tissues or tumour in this model. Finally, it is essential
to exclude the possibility that the growth delay is due to the modulators themselves
and these studies are also underway at present.
The choice of protocol for the administration of modulators was essentially empirical
but was based on the assumption that a second dose of modulator was neccessary
to maintain levels for several hours following epirubicin administration. In
retrospect this was a good idea but the study could perhaps be improved by a longer
administration of modulator and this will be attempted following a more detailed
study of quinidine pharmacokinetics in this model. It may of course be possible to
maintain the significant growth delay beyond 2-3 days by repeat dose of epirubicin.
Anthracyclines, however, can cause marked tissue necrosis in patients (Muggia &
Green, 1991) when extravasation occurs outwith the vein and as a result the mice
tails are usually inflamed after one tail vein injection making a repeat injection
often impossible. Furthermore the growth rate of this tumour (doubling time of
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2 days) suggests that the doses of epirubicin may have to be very close together and
the second dose may have to be reduced as a result leading to a possible loss of
effect. As described also in this study an attempt to use the intraperitoneal route
for epirubicin administration, for convenience and ease of repeat injections, led to
unacceptable toxicity. This observation is supported by a previous study which
described an increase in toxicity, manifest as early death and fibrosing peritonitis,
following intraperitoneal administration of doxorubicin in a rat model (Litterst et al,
1982). Furthermore there is evidence to suggest that the anti-tumour activity of
anthracyclines is decreased by this route of administration (Lenaz & Di Marco,
1972).
The drug distribution studies described in this Chapter are consistent with recent
publications which have suggested that, although increased intracellular drug levels
can be achieved by modulation of MDR cells in vitro, it appears to be a
redistribution of the drug within the cell may be the most important factor
(Schuurhuis et al, 1989; Coley et al, 1990a). The first of these studies showed that
modifiers like verapamil and ROl 1-2933 act by inducing redistribution of
doxorubicin from the cytoplasm to the nucleus of multidrug resistant cells in vitro.
This helps to explain how relatively small increases in intracellular drug
concentration ie. 1-2 fold have apparently been associated with large increases in
chemosensitivity ie. 10-12 fold (Plumb et al, 1990) and agrees with the results of the
tissue disposition study which suggest-that quinidine has little effect on the total
amount of drug in both tumour and other tissues. This failure to increase tumour
drug levels concurs with a previous study which examined the effect of verapamil on
vincristine concentrations in rhabdomyosarcoma xenografts in mice although in this
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study verapamil enhanced retention of vincristine in liver, kidney and small intestine
(Horton et al, 1989).
In summary the finding that the use of MDR modulators in combination with
epirubicin can cause a significant growth delay in a solid tumour known to be
resistant to epirubicin is an exciting breakthrough in the attempt to prove that P-
gp is a functional target in human tumours including breast cancer. The
confirmation of P-gp positive cells in the 2780AD xenograft, which could be
modulated in vitro, together with the demonstration of a redistribution of
intracellular epirubicin towards the nucleus with quinidine both support the theory
that the growth delay is due to an interaction of the two modulators, quinidine and
RO11-2933, with P-gp in vivo. If this is the case then the use of modulators of MDR
may have an important role to play in the treatment of MDR-positive human
tumours including carcinoma of the breast.
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CHAPTER 6
THE EFFECT OF ORAL OUINIDINE ON TUMOUR EPIRUBICIN
CONCENTRATION AND INTRACELLULAR DISTRIBUTION IN HUMAN
BREAST CANCERS.
INTRODUCTION
Several factors are thought to influence the delivery of cytotoxic drugs to
malignant cells in solid human tumours including the pharmcokinetics of the drug
itself, the vascularity of the tumour and the distribution of drug within the tumour.
In patients with advanced breast cancer the best single agents are anthracyclines
with a response rate of approximately 40% in previously untreated patients (Young
et al, 1981). This figure highlights the fact that over half the patients fail to
respond to this drug from the outset possibly due to inadequate drug delivery or
due to the presence of a population of resistant cells prior to chemotherapy. Since
doxorubicin has been detected in human breast cancer biopsies following a small
dose (25mg) intravenously (Stallard et al, 1990) drug delivery is probably not a
major problem. It is therefore more likely that drug delivery to MDR-positive
cells within the tumour is a major problem.
One way of attempting to improve drug delivery to resistant cells is to increase the
total tumour drug delivery by the use of "targeting" in an attempt to deliver high
concentrations of cytotoxic drugs to the tumour whilst reducing the delivery to
normal tissues. An examples of targeting is the use of vasopressive agents in the
delivery of loco-regional chemotherapy to hepatic metastases (Anderson et al,
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1991). Loco-regional therapy to the breast would be extremely difficult and at
present the total dose of epirubicin is limited by cumulative cardiotoxicity and the
dose intensity is restricted by myelosuppression and mucositis.(Muggia & Green,
1991). Any possible ways of increasing drug delivery to breast cancer cells would
therefore be extremely important.
The finding of a proportion of P-gp positive cells in the majority of 29 primary
breast cancers (see Chapter 2), together with the finding that MDR modulation
can increase intracellular drug concentration in MDR cells in vitro (see Chapter
4), has raised the possibility that circumventing agents may increase the drug
delivery to MDR positive cells in human breast cancers.
The study described in this Chapter was designed with two aims in mind. The first
was to determine whether quinidine could increase the total tumour epirubicin
concentration as a result of inhibition of the efflux pump in MDR positive cells.
The second aim was to examine the effect of quinidine on the intracellular
distribution of epirubicin in these tumours since it is now recognised that
circumvention of MDR cells can alter the pattern of distribution (Schuurhuis et
al, 1989) as described in the discussion in Chapter 4.
This study was carried out in patients with breast cancer rather than the mouse
xenograft model for several reasons. Firstly detailed drug distribution studies in
the mouse model will not answer the same question since the tumour vasculature
in the xenograft is quite different from human breast cancers. Secondly the
clinical trial of epirubicin and quinidine in patients with advanced breast cancer
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does not assess P-gp status for each patient and therefore any benefit to P-gp
positive patients may be hidden when all patients, both P-gp positive and negative,
are assessed together. This therefore is a more detailed study to determine
whether the principles of MDR modulation in vivo, as observed in the mouse
model, will apply to human tumours.
The rational for selection of quinidine as the modulator in this study was described
in Chapter 4. Epirubicin was chosen as the cytotoxic drug for study both to mimic
the combination used in the clinical trial and since the magnitude of the resistance
modulation with quinidine was much greater for epirubicin than doxorubicin.
The natural autofluorescence of epirubicin lends itself to distribution studies in
tumour sections and the elimination of out of focus epifluorescence by optical
sectioning, using confocal microscopy, allows the subcellular localisation of




A total of 15 women with histologically proven breast cancer were entered into the
study after informed consent was obtained. All patients were admitted for elective
surgery of early breast cancer at the University Departments of Surgery at the
Western Infirmary or the Royal Infirmary, Glasgow. The mean age of the patients
was 60.9 (range 48-75) and 4 patients underwent mastectomy while the other 11
had conservation surgery. Patients were excluded from study if there was a history
of cardiac or renal disease. In addition patients with impaired hepatic function
(bilirubin > 33qmol/l or AST > lOOjumol/l) were also excluded.
DRUG ADMINISTRATION
With the approval of the local ethical committee all patients in this study were
given a small dose of intravenous epirubicin approximately one hour before
surgery since a previous study had suggested this to be an optimal time for tissue
binding of another anthracycline, doxorubicin (Cummings et al, 1986). Since
doxorubicin has been detected in human breast cancers following a dose of 25mg
intravenously (Stallard et al, 1990) this dose was modified to 20mg/m2 to allow for
variations in patient size. In addition patients were randomised to pretreatment
with oral quinidine for four days prior to surgery or no pretreatment at all.
121
The dose of quinidine sulphate was 250mg/kg twice daily commencing in the
evening 4 days prior to the day of elective surgery (total dose 2g). At this dose
no side effects were encountered in a pilot study in the Beatson Oncology Centre,
Western Infirmary, Glasgow (Jones et al, 1990) whereas higher doses do lead to
increased levels of side effects.
On the day of surgery all 15 patients were given an intravenous bolus of epirubicin
(20mg/m2) into the side arm of a fast running drip approximately one hour before
the expected time of tumour excision. Following removal of the tumour the
samples were snap frozen in liquid Nitrogen and stored at -70°C until epirubicin
and DNA assays.
EPIRUBICIN ASSAY
The total epirubicin content (intracellular and extracellular) of the tumours was
quantified by High Pressure Liquid Chromatography (HPLC) using the same
method described in Chapter 5. Daunorubicin was again used as an internal
standard to estimate the extraction efficiency of the assay and epirubicin
concentrations were normalised by correcting for drug recovery. To allow for
differences in cellularity between tumours, which is often quite marked in breast




A 1:10 tissue to buffer homogenate was prepared by adding a nine-fold
weight/volume excess of PBS. To 0.5ml of tumour homogenate 3M NaAc (50ul)
was added with an equal volume of phenol and chloroform/isoamylalcohol (24:1
chloroform:isoamylalcohol), mixed for 15 minutes, then centrifuged at top speed
for ten minutes in a microfuge. The aqueous layer was removed and added to
0.5ml cool isopropanol (100%). The precipitated DNA was washed in 70%
ethanol, dried and resuspended in 1ml water. The optical density (OD260) was
read in a spectrophotometer (Perkin Elmer, Lambda 2, Beaconsfield, UK) and the
tumour DNA concentration calculated from a known standard. These tumour
DNA concentrations were used to calculate epirubicin concentrations as pg/mg
DNA.
INTRACELLULAR EPIRUBICIN DISTRIBUTION
The technique of confocal microscopy is described fully in the "methods" section
in Chapter 5. In brief 20jum sections were cut from four of the breast cancers, two
from patients given quinidine and two who did not receive quinidine. The sections
were unfixed and mounted in a water-based medium (Glycergel, Dako, High
Wycombe, England). The distribution of epirubicin in these sections was analysed
on a Carl Zeiss Laser Scan microscope (LSM 10) by confocal microscopy with
Argon laser excitation at 488nm. The sections were examined not to compare the
total amount of cellular fluorescence between different tumours but to look for




A total of 9 patients received epirubicin alone and 6 patients received epirubicin
in addition to oral quinidine. The mean sampling time was 64 minutes (range 45-
120) in the epirubicin group and 73 minutes (range 57-90) in the epirubicin and
quinidine group. The results of tumour epirubicin concentrations are shown in
Table 11. This shows no significant difference (p= 0.724) in the overall epirubicin
concentration between the groups treated with quinidine ( 0.815 ±_ 0.372 pg/mg
DNA) or no quinidine ( 0.714 4^0.182 pg/mg DNA) (Mann Whitney U Test).
TREATMENT EPIRUBICIN CONCENTRATION
(pg/mg DNA)
EPIRUBICIN ALONE 0.815 ±.0.372
EPIRUBICIN & QUINIDINE 0.714 +.0.182
TABLE 11
Tumour epirubicin concentration (mean +_ SD) in patients with breast cancer
treated with intravenous epirubicin alone and in patients treated with epirubicin
and oral quinidine pretreatment
SUBCELLULAR LOCALISATION OF EPIRUBICIN
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Fluorescence was detectable in all four breast cancer sections. The staining in
tumour cells was predominantly nuclear with some cytoplasmic staining. There
was no difference in intracellular distribution of drug with or without quinidine
either in tumour cells or stromal cells. Examples of the staining in tumour cells




Epirubicin subcellular localisation in sections of human breast cancers treated with
quinidine (a) and no quinidine (b). Both sections show a predominance of nuclear
epirubicin although some cytoplasmic fluorescence is also seen.
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DISCUSSION
The lack of difference in the total tumour epirubicin concentration between those
tumours exposed to epirubicin and quinidine and those exposed to epirubicin alone
is not altogether surprising. Given the small percentage of P-gp positive tumour
cells in most breast cancers it is unlikely that successful MDR modulation in these
cells, with small increases in intracellular drug concentrations, would have a
profound effect on the total amount of drug in the tumour. The range of tumour
epirubicin drug concentration in this study (423-1582 ng/mg DNA) shows a wide
inter-patient variation and these levels are consistent with a previous study where
doxorubicin (20mg) was given an hour before surgery (Stallard et al, 1990).
With the recent suggestion that MDR modulation may redistribute intracellular
drug in vitro (Schuurhuis et al, 1989) it seemed appropriate to look for any change
in the distribution of epirubicin in tumour cells in vivo. Although the number of
tumours was small this study failed to demonstrate any alteration in subcellular
localisation which could be attributed to the quinidine. It could be argued that the
subcellular distribution was not specifically looked at in P-gp positive cells in these
tumours. Unfortunately this was not possible since the small tumour specimens
were just sufficient for estimation of total tumour epirubicin levels and for the
thick sectioning (20pm) for con-focal microscopy. In addition the technique of
fixation required for immunohistochemical detection of P-gp interfered with the
preservation of fluorescence ruling out the possibility of looking at P-gp expression
and autofluorescence in the one section.
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The experiments described in this chapter confirm good penetration of epirubicin
in human breast cancers with nuclear localisation at subtherapeutic doses when
given approximately one hour before surgery. The use of con-focal laser
microscopy does provide high resolution images of subcellular localisation but it
is more likely to be of use in looking at those tumours with a higher percentage
of P-gp positive cells. This was highlighted in Chapter 4 where it was extremely
helpful in examining intracellular distribution of drug in a solid tumour model of
MDR, the 2780AD xenograft, with and without quinidine.
The use of quinidine has failed to provide any evidence that MDR modulation in
human breast cancer in any way "targets" the entire tumour and this was expected.
Whether the use of this drug specifically modulates MDR in the P-gp positive cells
in these tumours remains to be seen and this would hopefully be reflected by an
enhanced response to chemotherapy or improved patient survival in MDR-positive
tumours. It is possible however that the method used to measure tumour
epirubicin is not sensitive enough to detect 1-2 fold increases in MDR-positive
cells, as is observed in vitro, which may represent only between 1-10% of the total
tumour cell population.
Finally there was no obvious difference in autofluorescence in breast cancer
stromal cells with or without quinidine. It is possible that this small dose of
epirubicin fails to highlight the small spindle-shaped nuclei in stromal cells but the
lack of enhanced staining in these cells with quinidine suggests that the P-gp
present in these cells (see Chapter 3) may not respond to modulation in vivo. The
hypothesis that MDR modulation in breast cancer, with increased accumulation
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in stromal cells, may actually decrease the availability of cytotoxic drug for the
malignant cells in these tumours would appear to be unsubstantiated at present.
In conclusion this study once again demonstrates that cytotoxic drug delivery does
not appear to be a problem in the treatment of breast cancer. The study however
has failed to demonstrate an effect that could be attributed to MDR modulation
in vivo, either in total tumour or intracellular epirubicin., although the methods
used may not have been sensitive enough to detect small changes in intracellular
drug in MDR-positive cells. Although the results are somewhat disappointing the
rational for attempting MDR modulation in breast cancers with quinidine, based
on the P-gp expression study (Chapter 2) and successful MDR modulation with
quinidine in the mouse model (Chapter 5), is sound and even small, and as yet
undetected, changes in cytotoxic drug delivery to MDR-positive cells may influence
the growth of the tumour. The results of the clinical trial may answer these
questions although future trials may have to include a comparison of MDR-
positive and MDR-negative tumours when modulators are used to determine
whether modulation of MDR-positive cells in human breast cancer has an effect
on tumour response to cytotoxic drugs.
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CHAPTER 7
THE EFFECT OF ORAL OUINIDINE ON SYSTEMIC TOXICITY WITH
EPIRUBICIN IN PATIENTS WITH METASTATIC OR LOCALLY ADVANCED
BREAST CANCER.
INTRODUCTION
Chemotherapy is a useful palliative measure in the treatment of metastatic or locally
advanced breast cancer and the most successful single agents are anthracyclines with
a total response rate of 43% in previously untreated patients (Young et al, 1981).
The use of anthracyclines is associated with conventional toxicity eg.
myelosuppression, alopecia, nausea and vomiting as well as a more specific toxicity,
cardiomyopathy after a certain cumulative dose. The use of doxorubicin
(adriamycin) has now largely been superceded in the treatment of advanced breast
cancer in this country by epirubicin (4'- epidoxorubicin) which is thought to be less
cardiotoxic at an equivalent dose (Brambilla et al, 1986). The clinical use of
anthracyclines is not limited by this toxicity however but by the development of
clinical drug resistance.
One major route by which cells develop resistance to anthracyclines in vitro is
multidrug resistance (Seeber et al, 1982). This particular mechanism of resistance
is associated with expression of P-gp and this protein has been detected in the
majority of 29 primary breast cancers by immunohistochemistry using two
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monoclonal antibodies C219 and MRK16 (See Chapter 2). This protein, which acts
as a drug-efflux pump, can be reversed by a number of compunds in vitro including
quinidine (see Chapter 4). Since tumour quinidine levels which are adequate for in
vitro modulation of MDR can be achieved both in a MDR-positive mouse xenograft
and in human breast cancers, it would appear that in vivo modulation with this
compound may be possible. Furthermore the concentration of quinidine achieved
in the mouse model was capable of a significant increase in growth delay (see
Chapter 5) of the P-gp positive xenograft. This evidence therefore makes quinidine
an attractive choice as a potential MDR modulator in patients with breast cancer.
Before proceeding with quinidine as a MDR modulator in breast cancer patients it
is essential to know if this compound will be tolerated by the patients and if the
combination of quinidine and the cytotoxic drug is more toxic than the cytotoxic
alone. This theory of increased toxicity is based on the presence of P-gp in several
human tissues (Fojo et al, 1987) with possible increases in cytotoxic drug levels in
these organs , following modulation, leading to increased toxicity. In practice
however Jones et al (1990) have already shown that quinidine can be given, in
combination with epirubicin, to breast cancer patients without any increase in acute
toxicity. Furthermore this study also showed that patient compliance in taking oral
quinidine was good and the side effects from the quinidine alone were minimal.
Following this pilot study a Phase III, multicentre, clinical trial is presently ongoing,
coordinated by the West of Scotland Clinical Trials Group, to assess the effect of
oral quinidine on response to chemotherapy with epirubicin in patients with
metastatic or locally advanced breast cancer. The trial has a target figure of 260
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patients, 130 in each arm , in order to have enough patients to detect any survival
difference between the two arms of the trial as well as any difference in response to
chemotherapy. As the trial is still ongoing response data is not yet available but the
initial analysis can be used to answer some of the questions about toxicity when
modulators are used in patients. The systemic toxicity data in both the quinidine
and placebo arms of the trial has therefore been collated to look for any significant





Following randomization all patients are supplied with a six day course of capsules,
either quinidine 250 mg twice daily or placebo, in a double-blind fashion. The
course of capsules commences at 8pm on the fourth day prior to each course of
chemotherapy and finishes at 8pm on the second day following chemotherapy
(Figure 24).
DAY OF TREATMENT
-4 -3-2-1 0+1 +2






The timing of patient treatment with oral quinidine or placebo given with each
course of chemotherapy in a Phase III trial of epirubicin in patients with locally
advanced or metastatic breast cancer.
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All patients receive epirubicin 100mg/m2, dissolved in 25mis of water, into the side
arm of a fast running drip every three weeks for a maximum of eight courses. On
the morning following epirubicin a five day course of oral steroid (prednisolone
25mg twice daily) is commenced and appropriate anti-emetic treatment is given with
the epirubicin at the discretion of the clinician.
Prior to each cycle of chemotherapy each patient had a 5ml sample of blood taken
for quinidine estimation by immunoassay (for protocol see Method section in
Chapter 5.
PATIENT SELECTION
Eligibility criteria for entry into the study included histologically proven metastatic
or locally advanced breast cancer, measurable or evaluable disease and a World
Health Organisation (WHO) performance status 0,1 or 2. In addition patients
require to have adequate bone marrow function (haemoglobin > 10gm% ; total
white cells >4.0 x 109/1; platelet count > 100 x 109/1) and a normal serum bilirubin.
Patients are allowed to have received previous adjuvant chemotherapy (excluding
anthracyclines) and hormonal therapy as long as they are stopped prior to entry into
the study.
Reasons for exclusion from the study include prior chemotherapy for advanced
disease, inability to give informed consent or the presence of a second malignancy
(other than basal cell carcinoma of skin or carcinoma-in-situ of cervix). In addition
a previous history of myaesthenia gravis or hypersensitivity to quinidine are further
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reasons for exclusion as well as active peptic ulceration or another major
contraindication to oral steroids.
TREATMENT MODIFICATIONS
A 20% dose reduction of epirubicin is carried out if the total white blood cells are
less than 3.0 x 109/1 or if platelets are less than 100 x 109/1 on the day of treatment.
If the full blood count has not recovered after a maximum of two weeks patients are
removed from study. If grade III mucositis occurs epirubicin is deferred until
recovery has taken place and subsequent doses are reduced to 80mg/m2.
Side effects are not expected at the dose of quinidine given but can occasionally
include hypotension, ventricular arrhythmias or cinchonism (dizziness, tinnitus or
visual disturbance). If side effects are encountered the capsules are discontinued for
subsequent doses of quinidine withour breaking the randomization code.
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RESULTS
REASONS FOR STOPPING TREATMENT
Demographic data from the first 100 patients randomised shows the groups to be
well matched for age, performance status and prior hormone therapy (Table 12).
In the placebo (P) group 74.5% of patients completed three courses of chemotherapy
with 66.0% of them proceeding to >3 cycles. In the quinidine (Q) group 66.7%
completed three courses with 54.2% of these patients having further cycles of
chemotherapy. The reasons for stopping treatment at or before the third cycle are
summarised in Table 13. A total of 7 patients in group Q stopped treatment at or
or before the third cycle because of "excessive toxicity" in contrast to only 4 patients
in group P. In group P the main reason for this toxicity was haematological (3/4)
with the one other patient stopping due to uncontrollable vomiting post
chemotherapy. In group Q 3/7 patients stopped due to haematological toxicity and
the other four patients stopped for one of the following reasons: cerebrovascular
accident; breathlessness; phlebitis; prolonged vomiting.
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PLACEBO QUINIDINE
ECOG PERFORMANCE 0 27.7% 25.0%
STATUS 1 53.2% 54.6%
2 19.2% 20.8%
PRIOR HORMONE YES 72.3% 81.3%
TREATMENT NO 27.7% 18.7%
MEDIAN AGE 54 54
(RANGE) (29-74) (30-71)
TABLE 12
Patient characteristics in both placebo and quinidine arms of the trial showing both




PROGESSIVE DISEASE 8 9
PATIENT REFUSAL 3 0
EXCESSIVE TOXICITY 4 7
DEATH (UNKNOWN/NON CANCER) 1 2
INFECTED CENTRAL LINE 0 1
TABLE 13
Reasons for stopping treatment at or before the third cycle of chemotherapy in both
placebo and quinidine arms of the trial.
In the placebo arm 21.3% required epirubicin dose reductions for haematological
(n = 6) and other (n=4) toxicity. In contrast only 12.5% of patients in the quinidine
arm had dose reductions, two for haematological toxicity and two for other toxicity.
There was however a greater number of patients who had delays in epirubicin
treatment in the quinidine arm (22.9%) than the placebo arm (14.9%).
WHO grading of haematological toxicity, alopecia, nausea/vomiting, diarrhoea and
mucositis has shown no significant differences between placebo and quinidine limbs
of the trial (Table 14).
PLASMA OUINIDINE CONCENTRATION
A total of 197 plasma samples, from patients during cycles 1-3, had detectable levels
of quinidine. The mean steady-state level was 5.63pM (range 0.3-16.6 pM).
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WHO GRADE PLACEBO QUINIDINE























The percentage of patients, in both limbs of the trial, experiencing each systemic
toxicity according to the WHO grading system.
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DISCUSSION
Previous attempts to modulate multidrug resistant cells in human tumours have been
associated with increased systemic toxicity which has been related to the specific
modulator used. In this way the use of verapamil in combination with vincristine,
doxorubicin and dexamethasone (VAD) led to increased cardiotoxicity , manifest as
mild hypotension (8/8) and heart block(7/8), in eight patients with drug resistant
B-cell neoplasms previously treated with VAD alone (Dalton et al, 1989). Other
doxorubicin-related toxicities eg. myelosuppression and nausea/vomiting were not
however significantly increased by the addition of verapamil to VAD. This data
would concur with the findings described in this chapter which found no significant
differences in systemic toxicities when the combination of epirubicin and quinidine
is compared to epirubicin alone.
The toxicities in the various categories, graded according to WHO guidelines (see
Table 13), are very similar to the toxicities encountered in the high dose arm of a
study which compared high dose (lOOmg.m2 3 weekly) with low dose (50mg/m2 three
weekly) epirubicin (Habeshaw et al, 1991). There are two possible explanations why
the postulated increase in systemic toxicity with the addition of quinidine to
epirubicin does not appear to have occurred. Firstly, small increases in intracellular
cytotoxic drug concentrations in normal cells may not be enough to significantly alter
host toxicity despite the fact that these same increases in intracellular drug
concentrations in vitro can markedly alter chemosensitivity.
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A second explanation for the lack of increased toxicity with quinidine is that
intracellular drug concentrations in normal cells containing P-gp may not be
increased at all. This may arise as a result of a non-functional or an altered P-gp
molecule in normal cells, which is not affected by conventional modulators, or as a
result of inadequate tissue concentrations of quinidine. The finding of a mean
plasma quinidine concentration in 197 samples of 5.63,uM/l would seem to contest
the latter explanation since it is known that tumour quinidine concentrations, and
presumably tissue concentrations, are of the same magnitude as plasma levels (see
Chapter 4). Futhermore this mean plasma concentration of 5.63pM/l is a steady-
state level achieved after four days of oral therapy and is very close to the dose of
quinidine used in vitro which bring about near maximal reversal of MDR (6.6pM).
These findings with the use of quinidine in patients are consistent with the toxicity
obtained when quinidine and other modulators were administered to mice bearing
a MDR-positive xenograft (Chapter 5). Although a transient, reversible toxicity was
seen due to quinidine alone there was no increase in toxicity due to epirubicin. In
contrast 2 mice treated with epirubicin and verapamil died within the first 24 hours
after treatment. Whether this was due to the acute toxicity of verapamil alone or
to the combined toxicity of epirubicin and verapamil is not known. The use of
cytotoxic drugs themselves relies on the existence of a therapeutic window such that
drug concentrations that are toxic to the tumour are lower than those toxic to the
normal tissues. Likewise it is possible that the amount of the modulator required
to sensitize tumour cells is less than that required to sensitize normal tissues. On
this basis modulators may increase the therapeutic window of the drug.
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In conclusion these results indicate that oral quinidine can be used as a modulator
of MDR in patients with breast cancer without increasing patient systemic toxicity.
It remains to be seen whether oral quinidine at the dose used can improve the





The two main aims of this thesis were firstly to confirm the presence of P-gp in
human breast cancers and secondly to establish an in vivo model of MDR with
which to test known in vitro modulators of MDR to determine whether P-gp is
a functional target in human solid tumours. These aims have both been achieved
and they have led to some important findings regarding potential modulation of
MDR in human breast cancers. P-gp has been confirmed in human breast
cancers and has been localised not only to malignant cells but to breast cancer
stromal cells also. Although the expression in malignant cells predicted a worse
disease-free survival it was not related to other known prognostic factors. By
establishing a solid tumour model of MDR it was possible to demonstrate that
two modulators of MDR, quinidine and RO11-2933, could cause a significant
growth delay when given in combination with epirubicin. This led to an appraisal
of the effect of one of these modulators, quinidine, on epirubicin distribution in
human breast cancers with no apparent effect. The work in this thesis however
does provide a sound basis for a clinical trial of quinidine in patients with breast
cancer in an attempt to improve the response rate to epirubicin in patients with
locally advanced or metastatic breast cancer.
The use of chemotherapy in the treatment of breast cancer is compounded by the
development of drug resistance in a large number of cases. Although several
mechanisms of cellular drug resistance have been identified in vitro little is known
about the contribution these mechanisms make to the overall clinical drug
resistance of human breast cancers. One mechanism of drug resistance
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multidrug resistance (MDR), characterised by expression of a 170kDa
transmembrane protein (P-gp) which acts as a drug efflux pump, has been
identified in several human tissues and tumours but previous studies have failed
to provide clear evidence of its presence in breast cancer.
The detection of P-gp by immunohistochemistry using two monoclonal antibodies
(C219 & MRK16) is described in Chapter 2. This allowed confirmation of P-
gp, at low but variable levels, in the majority of 29 primary, untreated breast
cancers. This suggested that a population of resistant cells were present in breast
cancers before any exposure to cytotoxic drugs. The use of
immunohistochemistry in tumour sections however led to two other important
findings in addition to the confirmation of P-gp expression in these tumours.
Firstly the distribution of expression was found to be heterogeneous and secondly
this expression occurred not only in the malignant epithelial cells, as expected,
but in breast cancer stromal cells, thought to be myofibroblasts, also.
One advantage of this study was that the tumour samples were historical and this
allowed assessment of P-gp expression in relation to patient survival. Although
the numbers are small, and do not reach statistical significance, the results
suggest that those patient with the highest level of expression in tumour cells (
>5% of tumour cells ) have a worse prognosis in terms of disease-free survival
(p = 0.09). In contrast to this finding there was no similar association between P-
gp expression in stromal cells and prognosis.
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As mentioned previously two recent studies have identified a correlation between
P-gp expression and a poor response to chemotherapy in patients with advanced
breast cancer (Verrelle et al, 1991; Ro et al, 1990). Unlike these studies the
poor prognosis associated with P-gp expression in the patients described in
Chapter 2 is apparently unrelated to a poor response to chemotherapy since only
three of six patients who received adjuvant chemotherapy were exposed to MDR-
related drugs. It is possible that P-gp expression may be a biological marker of
tumour aggression in breast cancer and this may explain both a poor response to
chemotherapy and a worse disease-free survival. This hypotheseis would be
supported by a recent study of colonic carcinomas which found that P-gp positive
colon cancer cells have an increased potential for dissemination (Weinstein et al,
1991).
If P-gp expression in breast cancer is associated with local tumour invasion and
dissemination then measurement of P-gp, together with other known prognostic
factors may help to identify patients who would benefit from adjuvant therapy.
Alternatively measurement of this protein in patients with locally advanced or
metastatic breast cancer could select MDR-positive tumours such that these
patients could receive appropriate treatment. Either anthracyclines can be
avoided or modulating agents such as quinidine could be incorporated into their
treatment.
The findings reported in Chapter 3 suggest that the immunoreactivity in breast
cancer stromal cells represents true expression of P-gp. The use of peptide
blocking of the monoclonal antibody prior to incubation with tumour sections,
which confirmed genuine P-gp expression in these stromal cells, provides a more
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specific negative control when using C219 and should be used routinely instead
of omission of the primary antibody or substitution by an irrelevant antibody.
Although the function of P-gp in these stromal cells is not yet known it is
conceivable that it has a secretory role in these cells and may even secrete
stromal products which are important in promoting tumour invasion or metastasis
eg. Stromelysin 3 (Basset et al, 1990). If this hypothesis can be proven then these
stromal cells, or their products, may become specific targets for anti-cancer
therapy.
By examination of paired tumour and "normal" breast specimens from the same
patient it was possible to show that stromal cells in normal breast do not express
P-gp. Thus P-gp expression would appear to be specific to breast cancer stromal
cells and future studies should address how it it may arise in these tumours. P-
gp however was expressed in some ductal epithelial cells in normal breast in 2/9
patients and it is of interest that these patients also had the tumours with the
highest number of P-gp positive stromal cells.
The finding that the MDR phenotype may be partially reversed in vitro by
specific compounds which interact with P-gp is not new. It was however
important to confirm that known circumventing agents could modulate a breast
carcinoma cell line (MCF7ADR) in vitro (see Chapter 4) prior to attempting
modulation of drug resistant solid tumours and ultimately human breast cancers.
By using the MTT microtitration assay it was possible to demonstrate a
modulating effect by tamoxifen, verapamil and quinidine and furthermore
quinidine also enhanced doxorubicin uptake in the same cells. Quinidine was
therefore selected for further study since it has been used for many years as an
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anti-arrthythmic agent and there is already evidence to suggest that plasma levels
suitable for modulation are non-toxic. The studies described in Chapter 4 also
highlighted the finding that the combination of quinidine (6.6pM) and epirubicin
produced a much higher increase in chemosensitivity (22.5-fold) than the
combination of quinidine (6.6pM) and doxorubicin (7-fold).
Although there are now many compounds, including quinidine, which modulate
MDR cells in vitro it is much more difficult to show a similar effect in vivo. A
pre-requisite for attempting to modulate MDR cells in vivo is the attainment of
tumour, as well as plasma, levels adequate for MDR modulation. Since many
MDR modulators are highly protein-bound in plasma it was therefore extremely
encouraging to find that quinidine levels, in the range known to modulate MDR
cells in vitro, could be achieved both in an animal solid tumour model of MDR
and in human breast cancers (Chapter 4).
The paucity of effective in vivo modulator studies almost certainly is a reflection
of the difficulty in establishing a good solid tumour model of MDR cells with
which to test potential modulators. The use of the 2780AD xenograft in nude
mice was not without difficulty since intraperitoneal epirubicin proved extremely
toxic to the mice (Chapter 5). In this same model quinidine did not increase
tumour or tissue epirubicin concentrations and this result is consistent with recent
recognition that it may be a redistribution of drug within the cell which is
important in MDR modulation rather than small increases in total intracellular
drug levels (Schuurhuis et al, 1989).
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The most encouraging result from the xenograft studies was the finding that
quinidine, in combination with epirubicin, caused a significant growth delay in the
2780AD xenograft at day 2 when compared with an untreated group (p< 0.001)
and the group treated with epirubicin alone (p = 0.01). Although this significant
growth delay appears to be maintained at days 5 and 7, when depicted graphically
(Figure 19), the enhancement of the growth delay does not reach statistical
significance due to the size of the standard errors within the groups at these time
points.
This improved growth delay with quinidine appears to represent true MDR
modulation since P-gp expression was confirmed in the 2780AD xenograft and
cells derived from one of the untreated group could be modulated in a MTT
microtitration assay. Furthermore the use of confocal laser microscopy has shown
that quinidine can cause a redistribution of intracellular epirubicin in this model
with increased nuclear fluorescence in the quinidine-treated group compared to
the group treated with epirubicin alone.
The combination of oral quinidine, at doses known to be adequate for MDR
modulation (Chapter 4), and intravenous epirubicin can be given to patients
without any apparent increase in systemic patient toxicity (Chapter 7). Quinidine
at this dose however did not increase total tumour epirubicin levels in human
breast cancers nor did it appear to affect intracellular epirubicin distribution
(Chapter 6). A more definitive test of the hypothesis that MDR-positive cells
in human breast cancer can be modulated with quinidine will be the outcome of
the clinical trial described in Chapter 7. In this trial the effect of oral quinidine
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is being assessed on the response to chemotherapy and patient survival in patients
with locally advanced or metastatic breast cancer treated with epirubicin. If this
trial shows an improvement either in response to chemotherapy or patient
survival in the quinidine arm of the trial then this will be an exciting advance in
the use of chemotherapy in breast cancer. If on the other hand there is no
difference with or without quinidine then there are several reasons why this may
arise.
Although data on P-gp expression is available for a small number of patients in
the trial one concern is that any benefit to P-gp positive tumours may be hidden
when all tumours, P-gp negative and positive, are considered together. In
addition it is possible that the number of P-gp positive cells in the MDR-positive
tumours may be too small to have a significant effect on the whole tumour when
modulation is attempted.
The most likely scenario is that several mechanisms of resistance will be present
in any one tumour and may include for example alterations in Topoisomerase
enzymes or alterations in glutathione-S-transferase levels. The first of these
mechanisms may well be extremely important in breast cancer following the
recent recognition that alterations to Topoisomerase loci in breast cancer is a
relatively frequent event (Keith, personal communication). Since different
resistance mechanisms may be more or less important from tumour to tumour
future attempts to combat clinical drug resistance may have to combine stategies
to overcome several different mechanisms of resistance. This may involve the use
of so called modulators which interact with each mechanism, in the same way as
quinidine and P-gp, or by development of new cytotoxic agents which are
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designed to be unaffacted by known resistance mechanisms. In this way the
morpholinyl anthracyclines, which are not substrates for the P-gp pump and which
can restore drug-resistant cell lines to nearly the same sensitivity as the drug-
sensitive parent lines, have been developed (Coley et al, 1990b; Watanabe et al,
1991).
In summary the confirmation of P-gp expression in human breast cancer together
with the finding that quinidine can modulate P-gp positive cells in a solid tumour
model of MDR provide a sound basis for attempts to modulate MDR-positive
cells in human breast cancers. A clinical trial is currently ongoing to assess this




Akiyama S, Shiraishi N, Kuratami Y, Nakagawa M & Kuwano M (1986).
Circumvention of multiple-drug resistance in human cancer cells by thioridazine,
trifluoperazine and chlorpromazine. J Natl. Cancer Inst., 76: 839-844.
Anderson JH, Goldberg JA, Eley JG & 5 others (1991). A phase 1 study of
regionally administered Mitomycin C microcapsules for patients with colorectal
cancer. Br. J Cancer, 63 (supp XIII): 36.
Barskv SH, Green WR, Grotendorst GR & Liotta LA (1984). Desmoplastic breast
carcinoma as a source of human myofibroblasts. Am. J Pathol., 115: 329-333.
Basset P, Bellocq JP, Wolf C & 7 others (1990). A novel metalloproteinase gene
specifically expressed in stromal cells of breast carcinomas. Nature, 348: 699-704.
Batist G, Tulpule A, Sinha BK, Myers CE & Cowan KEI (1986). Overexpression of
a novel anionic glutathione transferase in multidrug-resistant human breast cancer
cells. J Biol. Chem., 261: 15544-15549.
Beck WT, Cirtain MC, Look AT & Ashmun RA (1986). Reversal of Vinca alkaloid
resistance but not multiple drug resistance in human leukaemic cells by verapamil.
Cancer Res., 46: 778-784.
151
Beck WT (1987). The cell biology of multiple drug resistance. Biochem. Pharmacol.,
36: 2879-2887.
Biedler JL & Riehm II (1970). Cellular resistance to actinomycin D in Chinese
hamster cells in vitro: cross-resistance, radioautographic and cytogenetic studies.
Cancer Res., 30: 1174-1184.
Borresen AL, Ottestad L, Gaustad X & 5 others (1990). Amplification and protein
overexpression of the neu/WER-2/c-erhB2 protooncogene in human breast
carcinomas: relationship to loss of gene sequences on chromosome 17, family history
and prognosis. Br J Cancer, 62: 585-590.
Bradley G, Georges E & Ling V (1990). Sex-dependent and independent expression
of the P-glycoprotein isoforms in Chinese hamster. J Cell. Physiol., 145: 398-408.
Brambilla C, Rossi A, Bonfante V & 4 others (1986). Phase II study of doxorubicin
versus epirubicin in advanced breast cancer. Cancer Treatment Reports, 70: 261-
266.
Brinkley D & Haybittle JL (1984). Long term survival of women with breast cancer.
Lancet, I: 1118.
Carter SK, Selawry O & Slavik M (1977).
Monogr., 45: 75-80.
Chan IISL, Thorner PS, Haddad G &
detection of P-glycoprotein: prognostic
childhood. J Clin. Oncol., 8: 689-704.
152
Phase I clinical trials. Natl. Cancer Inst.
Ling V (1990). Immunohistochemical
correlation in soft tissue sarcoma of
Chatterjee M, Robson CN & Harris AL (1990). Reversal of multidrug resistance by
verapamil and modulation by alpha-1 acid glycoprotein in wild-type and multidrug-
resistant Chinese hamster ovary cell lines. Cancer Res., 50: 2818-2822.
Chauffert B, Rey D, Condert B, Durmas M & Martin F (1987). Amiodarone is
more efficient than verapamil in reversing resistance to anthracyclines in tumour
cells. Br. J Cancer, 56: 119-122.
Chen CJ, Chin JE, Ueda K, Clarke DP, Pastan I, Gottesman M & Roninson IB
(1986). Internal duplication and homology to bacterial transport proteins in the mdr-
1 (P-glycoprotein) gene for multidrug-resistant human cells. Cell, 47: 381-389.
Coley PIM, Workman P, Twentyman PR & Amos WB (1990a). Confocal microscopy
of anthracycline subcellular localization in classic and atypical multidrug resistance.
Br. J Cancer, 62: 512.
Coley HM, Twentyman PR & Workman P (1990b). 9-Alkyl, morpholinyl
anthracyclines in the circumvention of multidrug resistance. Eur. J Cancer, 26: 665-
667.
Coons AH & Kaplan MH (1950). Localization of antigen in tissue cells. J Exp.
Med., 91: 1-13.
Cornwell MM, Safa AR, Felsted RL, Gottesman MM & Pastan I (1986). Membrane
vesicles from multidrug-resistant human cancer cells contain a specific 150-170 kDa
protein detected by photoaffinity labeling. Proc. Nad. Acad. Sci., 83: 3847-3850.
Cornwell MM, Pastan I & Gottesman MM (1987). Certain calcium channel blockers
bind specifically to multidrug-resistant human KB carcinoma membrane vesicles and
inhibit drug binding to P-glycoprotein. J Biol. Chem., 262: 2166-2170.
Cramer G & Isaakson B (1963). Quantitative determination of quinidine in plasma.
Scand. J Clin. Lab. Invest., 15: 553-556.
Cummings J & McArdle CS (1986). Studies on the in vivo disposition of adriamycin
in human tumours which exhibit different responses to the drug. Br. J Cancer, 53:
835-838.
154
Dalton WS, Grogan TM, Meltzer PS & 5 others (1989). Drug-resistance in multiple
myeloma and non-Hodgkins lymphoma: detection of P-glycoprotein and potential
circumvention by addition of verapamil to chemotherapy. J Clin. Oncol., 7: 415-
424.
De Coursey TE, Chandy KG, Gupta S & Cahalan MD (1985). Voltage-dependent
ion channels in T-lymphocytes. J Neuroimmunol., 10: 71-95.
Early Breast Cancer Trialists' Collaborative Group (1988). Effects of adjuvant
tamoxifen and of cytotoxic therapy on mortality in early breast cancer. New Engl.
J Med., 319: 1681-1692.
Epstein PM, Fiss K, Hachisu R & Andrenyak DM (1982). Interaction of calcium
antagonists with cyclic AMP phosphodiesterases and calmodulin. Biochem. Biophys.
Res. Commun., 105: 1142-1149.
Fairchild CR, Ivy SP, Kao-shan CS & 6 others (1987). Isolation of amplified and
overexpressed DNA sequences from adriamycin-resistant human breast cancer cells.
Cancer Res., 47: 5141-5148.
Fojo AT, Akiyama SI, Gottesman MM & Pastan I (1985). Reduced drug
accumulation in multiple drug-resistant human KB carcinoma cell lines. Cancer Res.,
45: 3002-3007.
155
Fojo AT, Ueda K, Slamon DJ, Poplack DG, Gottesman MM & Pastan I (1987).
Expression of a multidrug-resistance gene in human tumours and tissues. Proc. Natl.
Acad. Sci. USA., 64: 265-269.
Ganapathi R & Grabowski D (1983). Enhancement of sensitivity to adriamycin in
resistant P388 leukaemia by the calmodulin inhibitor trifluoperazine. Cancer Res.,
43: 3696-3699.
Gerlach JH, Endicott JA, Juranka PF & 4 others (1986). Homology between P-
glycoprotein and a bacterial haemolysin transport protein suggests a model for
multidrug resistance. Nature, 324: 485-489
Gilson E, Nikaido H & Hofnung M (1982). Sequence of the rnalK gene in E. coli
K12. Nucleic Acids Res., 10: 7449-7458.
Goldstein LJ, Galski H, Fojo A & 11 others (1989). Expression of a multidrug
resistance gene in human cancers. J Natl. Cancer Inst., 81: 116-124.
Gottesman MM & Pastan I (1988). The multidrug transporter, a double edged
sword. J Biol. Chem., 263: 12163-12166.
156
Grey AM, Schor AM, Rushton G, Ellis I & Schor SL (1989). Purification of the
migration stimulating factor produced by fetal and breast cancer patient fibroblasts.
Proc. Natl. Acad. Sci. USA, 86: 2438-2442.
Gros P, Croop J & Ilousman D (1986). Mammalian multidrug resistance gene:
complete cDNA sequence indicates strong homology to bacterial transport proteins.
Cell, 47: 371-380.
Habeshaw T, Paul J, Jones R & 7 others (1991). Epirubicin at two dose levels with
prednisolone as treatment for advanced breast cancer: the results of a randomized
trial. J Clin. Oncol., 9: 295-304.
Haggie J, Howell A, Sellwood RA, Birch JM & Schor SL (1987). Fibroblasts from
relatives of patients with hereditary breast cancer show fetal-like behaviour in vitro.
Lancet, i: 1455-1457.
Hamada H, Hagiwara KI & Tsuruo T (1987). Phosphorylation of the Mf 170,000 to
180,000 glycoprotein specific to multidrug-resistant tumor cells: effects of verapamil,
trifluoperazine and phorbol esters. Cancer Res., 47: 2860-2865.
157
Hamilton TC, Winker MA, Louie KG & 7 others (1985). Augmentation of
adriamycin, melphelan and cisplatin cytotoxicity in drug-resistant and sensitive human
ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione
depletion. Biochem. Pharmacol., 34: 2583-2586..
Harrow JA & Dhalla NS (1976). Effects of quinidine on calcium transport activities
of the rabbit heart mitochondria and sarcotubular vesicles. Biochem. Pharmacol.,
25: 897-902.
Hickson ID, Turley H, Gattei K & Harris AL (1991). A non P-glycoprotein, 150kd
transmembrane protein associated with multidrug resistance. Br. J Cancer, 63 (Supp.
XIII): 13.
Higgins CF, Hiles ID, Salmond GPC & 8 others (1986). A family of related ATP-
binding subunits coupled to distinct biological processes in bacteria. Nature, 323:
448-450.
Horton JK, Thimmaiah KN, Houghton JA, Horowitz ME & Houghton PJ (1989).
Modulation by verapamil of vincristine pharmacokinetics and toxicity in mice bearing
human tumour xenografts. Biochem. Pharmacol., 38: 1727-1736.
158
Inaba M & Johnson RK (1978). Uptake and retention of adriamycin and
daunorubicin by sensitive and anthracycline-resistant sublines of P388 leukaemia.
Biochem. Pharmacol., 27: 2123-2130.
Iven H (1977). The pharmacokinetics and organ distribution of ajmaline and
quinidine in the mouse. Arch. Pharmacol., 298: 43-50.
Jones RD, Kerr DJ, Harnett AN, Rankin EM & Kaye SB (1990). A pilot study of
quinidine and epirubicin in the treatment of advanced breast cancer. Br. J Cancer,
62: 133-135.
Juliano RL & Ling V (1976). A surface glycoprotein modulating drug permeability
in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta, 455: 152-162.
Kahan BD, Ried M & Newburger J (1983). Pharmacokinetics of cyclosporin in
human renal transplantation. Transplant. Proc., 15: 446-453.
Kartner N, Evernden-Porelle D, Bradley G & Ling V (1985). Detection of P-
glycoprotein in multidrug-resistant cell lines by monoclonal antibodies. Nature, 316:
820-823.
Keith WN, Stallard S & Brown R (1990). Expression of mdr-1 and gst-pi in human
breast tumours: comparison to in vitro chemosensitivity. Br. J Cancer, 61: 712-716.
159
Kerr DJ, Graham J, Cummings J & 4 others (1986). The effect of verapamil on the
pharmacokinetics of adriamycin. Cancer Chemother. Pharmacol., 18: 239-242.
Kessel D, Botterill V & Wodinsky I (1968). Uptake and retention of daunomycin
by mouse leukaemic cells as factors in drug response. Cancer Res., 28: 938-941.
Kuratani Y, Akiyama S, Ono M, Shiraishi N, Shimada R, Ohkuma S & Kuwano M
(1986). Thioridazine enhances lysosomal accumulation of epidermal growth factor
with Pseudomonas exotoxin. Exp. Cell. Res., 162: 436-448.
Lenaz L & Di Marco A (1972). On the reported lack of daunomycin (NSC-82151)
and adriamycin (NSC-123127) on solid tumours. Cancer Chemother. Rep., 56:431-
432.
Litterst CL, Collins JM, Lowe MC, Arnold ST, Powell DM & Guarino AM (1982).
Local and systemic toxicity resulting from large-volume administration of doxorubicin
in the rat. Cancer Treatment Reports, 66: 157-161.
Ma DDF, Davey RA, Harman & 5 others (1987). Detection of a multidrug resistant
phenotype in acute non-lymphoblastic leukaemia. Lancet, i: 135-137.
160
Mason DT, DeMaria AN, Amsterdam EA & 6 others. Antiarrhythmic agents:
mechanisms of action, clinical pharmacology and therapeutic considerations. In BS
Avery (Ed), Cardiovascular Drugs, Vol 1, Antiarrhythmic, Antihypertensive and
Lipid Lowering Drugs. ADIS Press, Sydney, 1977, p87.
Mattern J, Bak M & Volm M (1987). Occurrence of a multidrug-resistant phenotype
in human lung xenografts. Br. J Cancer, 56: 407-411.
Merkel DE, Fuqua AW, Tandon AK, Hill SM, Buzdar AU & McGuire WL (1989).
Electrophoretic analysis of 248 clinical breast cancer specimens for P-glycoprotein
expression or gene amplification. J Clin. Oncol., 8: 1129-1136.
McGrath T & Center MS (1987). Adriamycin resistance in HL60 cells in the
absence of detectable P-glycoprotein. Biochem. Biophys. Res. Commun., 145: 1171-
1176.
Miller TP, Grogan TM, Dalton WS, Spier SM, Scheper RJ & Salmon SE (1991). P-
glycoprotein expression in malignant lymphoma and reversal of clinical drug
resistance with chemotherapy plus high-dose verapamil. J Clin. Oncology, 9(1): 17-24.
Muggia FM & Green MD (1991). New anthracycline antitumor antibiotics. Critical
Rev. Oncol. Haematol., 11: 43-64.
Nakane PK & Pierce GB (1966). Enzyme labelled antibodies: preparation and
application for the localisation of antigens. J Histochem. Cytochem., 14: 928-931.
161
Ng WF, Sarangi F, Zastawny RL, Veinot-Drebot L & Ling V (1989). Identification
of members of the P-glycoprotein multigene family. Moll. Cell. Biol., 9: 1224-1232.
Ozols RF, Cunnion RE, Klecker RW & 4 others (1987). Verapamil and adriamycin
in the treatment of drug-resistant ovarian cancer patients. J Clin. Oncol., 5: 641-
647.
Piafsky KM, Borga O, Odar-Cederlof I, Johansson C & Sjoqvist F (1978). Increased
plasma protein binding of propranolol and chlorpromazine mediated by disease-
induced elevations of plasma alpha-1 acid glycoprotein. New Engl. J Med., 299:
1435-1439.
Plumb JA, Milroy R & Kaye SB (1989). Effects of the pH dependence of 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide-formazan absorption on
chemosensitivity determined by a novel tetrazolium-based assay. Cancer Res., 49:
4435-4440.
Plumb JA, Milroy R & Kaye SB (1990). The activity of verapamil as a resistance
modifier in vitro in drug resistant human tumour cell lines is not stereospecific.
Biochem. Pharmacol., 39: 787-792.
162
Radel S, Bankusli I, Mayhew E & Rustum YM (1988). The effects of verapamil and
a tiapamil analogue, DMDP, on adriamycin-induced cytotoxicity in P388 adriamycin-
resistant and sensitive leukemia in vitro and in vivo. Cancer Chemother. Pharmacol.,
21: 25-30.
Ramu A, Glaubiger D & Fuks Z (1984). Reversal of acquired resistance to
doxorubicin in P388 cells by tamoxifen and other triparamol analogues. Cancer
Res., 44: 4392-4396.
Reeve JG, Rabbits PH & Twentyman PR (1990). Non-P-glycoprotein-mediated
multidrug resistance with reduced EGF receptor expression in a human large cell
lung cancer cell line. Br. J Cancer, 61: 851-855.
Riordan JR, Deuchars K, Kartner N, Alon N, Trent J & Ling V (1985).
.Amplification of P-glycoprotein genes in multidrug-resistant mammalian cell lines.
Nature, 316: 817-819.
Ro J, Sahin A, Ro JY, Fritsche H, Hortobagyi G & Blick M (1990).
Immunohistochemical analysis of P-glycoprotein expression correlated with
chemotherapy resistance in locally advanced breast cancer. Hum. Pathol., 21: 787-
791.
163
Rothenberg M & Ling V (1989). Multidrug resistance: molecular biology and
clinical relevance. J Natl. Cancer Inst., 81: 907-910.
Sakakura T, Sakagami Y & Nishizuka Y (1981). Accelerated mammary cancer
development by fetal salivary mesenchyma isografted to adult mouse mammary
epithelium. J Natl. Cancer Inst., 66: 953-957.
Salmon SE, Grogan TM, Miller T, Scheper R & Dalton WS (1989). Prediction of
doxorubicin resistance in vitro in myeloma, lymphoma and breast cancer by P-
glycoprotein staining. J Natl. Cancer Inst., 81: 696-701.
Schlaifer D, Laurent G, Chittal S & 8 others (1990). Immunohistochemical
detection of multidrug resistance associated P-glycoprotein in tumour and stromal
cells of human cancers. Br. J Cancer, 62: 177-182.
Schneider J, Bak M, Efferth T, Kaufmann M, Mattern J & Volm M (1989). P-
glycoprotein expression in treated and untreated human breast cancer. Br. J Cancer,
60: 815-818.
Schuurhuis GJ, Broxterman HJ, Cervantes A & 5 others (1989). Quantitative
determination of factors contributing to doxorubicin resistance in multidrug-resistant
cells. J Natl. Cancer Inst., 81: 1887-1892.
164
Seeber S, Osieka R, Schmidt CG, Achterrath W & Crooke ST (1982). In vivo
resistance towards anthracyclines, etoposide and cw-diamminedichloroplatinum(II).
Cancer Res., 42: 4719-4725.
Shen D-W, Fojo A, Roninson IB & 5 others (1986). Multidrug resistance of DNA-
mediated transformants is linked to transfer of the human mdr-1 gene. Moll. Cell.
Biol., 6: 4039-4044.
Skovsgaard T (1978). Mechanisms of resistance to daunorubicin in Ehrlich ascites
tumor cells. Cancer Res., 38: 1785-1791.
Slater LM, Sweet P, Stupecky M & Gupta S (1986a). Cyclosporin A reverses
vincristine and daunorubicin resistance in acute lymphatic leukaemia in vitro. J Clin.
Invest., 77: 1405-1408.
Slater LM, Sweet P, Stupecky M, Wetzel MW & Gupta S (1986b). Cyclosporin A
corrects daunorubicin resistance in Ehrlich ascites carcinoma. Br. J Cancer, 54: 235-
238.
Smith PJ (1990). DNA topoisomerase dysfunction: a new goal for antitumor
chemotherapy. Bioessays, 12: 167-172.
165
Snyder S & Ashwell G (1971). Quantitation of specific serum glycoproteins in
malignancy. Clinica. Chimica. Acta., 34: 449-455.
Stallard S, Morrison JG, George WD & Kaye SB (1990). Distribution of
doxorubicin to normal breast and tumour tissue in patients undergoing mastectomy.
Cancer Chemother. Phartnacol., 25: 286-290.
Sugawara I, Kataoka I, Morishita Y & 4 others (1988). Tissue distribution of P-
glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal
antibody, MRK16. Cancer Res., 48: 1926-1929.
Surewicz WK & Jozwiak Z (1983). Effect of quinidine on membrane properties.
Depression of the lipid phase transition temperature and changes in the permeability
of the lipid bilayer. Biochem. Pharmacol., 32: 1467-1471.
Tan KB, Mattern MR, Eng W-K, McCabe FL & Johnson RK (1989).
Nonproductive rearrangement of DNA topoisomerase I and II genes: correlation
with resistance to topoisomerase inhibitors. J Natl. Cancer Inst., 81: 1732-1735.
Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I & Willingham MC
(1987). Cellular localization of the multidrug-resistance gene product P-glycoprotein
in normal human tissue. Proc. Natl. Acad. Sci. Usa, 84: 7735-7738.
166
Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I & Willingham MC
(1989). Immunohistochemical localization in normal tissues of different epitopes in
the multidrug transport protein P170: evidence for localization in brain capillaries
and crossreactivity of one antibody with a muscle protein. J Histochem. Cytochem.,
37: 159-164.
Tremblay G (1979). Stromal aspects of breast cancer. Exp. Mol. Pathol., 31: 248-
260.
Tsuruo T, Iida H, Tsukagoshi S & Sakurai Y (1981). Overcoming of vincristine
resistance in P388 leukaemia in vivo and in vitro through enhanced cytotoxicity of
vincristine and vinblastine by verapamil. Cancer Res., 41: 1967-1972.
Tsuruo T, Iida H, Tsukagoshi S & Sakurai Y (1982). Increased accumulation of
vincristine and adriamycin in drug-resistant tumor cells following incubation with
calcium antagonists and calmodulin inhibitors. Cancer Res., 42: 4730-4733.
Tsuruo T, Iida H, Nojiri M, Tsukagoshi S & Sakurai Y (1983). Circumvention of
vincristine and adriamycin resistance in vitro and in vivo by calcium influx blockers.
Cancer Res., 43: 2905-2910.
167
Tsuruo T, Iida H, Kitatani Y, Yokota K, Tsukagoshi S & Sakurai Y (1984). Effects
of quinidine and related compounds on cytotoxicity and cellular accumulation of
vincristine and adriamycin in drug-resistant tumor cells. Cancer Res., 44: 4303-4307.
Twentyman PR, Fox NE & White DJG (1987). Cyclosporin A and its analogues as
modifiers of adriamycin and vincristine resistance in a multidrug resistant human
lung cancer cell line. Br. J Cancer, 56: 55-57.
Twentyman PR (1988). Modification of cytotoxic drug resistance by non-
immunosuppressive cyclosporins. Br. J Cancer, 57: 254-258.
Van den Hooff A (1988). Stromal factors in malignant growth. Adv. Cancer Res.,
50: 159-196.
Verrelle P, Meissonnier F, Fonck Y & 5 others (1991). Clinical relevance of
immunohistochemical detection of multidrug resistance P-glycoprotein in breast
carcinoma. J Natl. Cancer Inst., 83: 111-116.
Volm M, Efferth T, Bak M, Ho AD & Mattern J (1989). Detection of the multidrug
resistant phenotype in human tumours by monoclonal antibodies and the
streptavidin-biotinylated phycoerythrin complex method. Eur. J Cancer. Clin. Oncol.,
25: 743-749.
168
Watanabe M, Komeshima N, Naito M, Isoe T, Otake N & Tsuruo T (1991).
Cellular pharmacology of MX2, a new morpholino anthracycline in human
pleiotropic drug-resistant cells. Cancer Res., 51: 157-161.
Weenen H, Lankelma J, Penders PGM, McVie JG, Ten Bokkel Huiinink WW, de
Planque MM & Pinedo MM (1983). Pharmacokinetics of 4'-epi-doxorubicin in man.
Invest. New Drugs, 1: 59-64.
Weinstein RS, Jakate SM, Dominguez JM & 8 others (1991). Relationship of the
expression of the multidrug resistance gene product (P-glycoprotein) in human colon
carcinoma to local tumor aggressiveness and lymph node metastasis. Cancer Res.,
51: 2720-2726.
Wishart GC, Plumb JA, Going JJ & 4 others (1990 a). P-glycoprotein expression in
primary breast cancer detected by immunocytochemistry with two monoclonal
antibodies. Br. J Cancer, 62: 758-761.
Wishart GC, Plumb JA, Going JJ, McNicol AM, McArdle CS & Kaye SB (1990 b).
Is C219 specific for P-glycoprotein? Br. J Cancer, 62: 534.
Yin M-b, Bankusli I & Rustum YM (1989). Mechanisms of the in vivo resistance
to adriamycin and modulation by calcium channel blockers in mice. Cancer Res.,
49: 4729-4733.
169
Young RC, Ozols RF, Myers CE (1981). The anthracycline antineoplastic drugs.
New Eng J Med, 305: 139-153.
Yusa K & Tsuruo T (1989). Reversal mechanism of multidrug resistance by
verapamil: direct binding of verapamil to P-glycoprotein on specific sites and
transport of verapamil outward across the plasma membrane of K562/ADM cells.
Cancer Res., 49: 5002-5006.
Zhang H, D'Arpa P & Liu LF (1990). A model for tumor cell killing by
topoisomerase poisons. Cancer Cells, 2: 23-27.
Zijilstra JG, De Jong S, De Vries EGE & Mulder NH (1990). Topoisomerases, new
targets in cancer chemotherapy. Med. Oncol. & Tumor Pharmacother., 7: 11-18.
